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Abstract 
 
Loss of function associated with breakdown of the blood-brain barrier 
in the central nervous system: an in vivo study 
 
 
Blood-brain barrier breakdown is a common feature of neuroinflammatory diseases, such 
as multiple sclerosis (MS). Indeed, blood proteins may play a role in the pathology of the 
disease. Here we investigate the link between the presence of blood-borne components in 
the CNS parenchyma and the expression of neurological deficits.  
 
Male Sprague-Dawley rats were injected intraspinally with vascular endothelial growth 
factor (VEGF), which causes breakdown of the blood-brain barrier, or saline as control. The 
injection was made unilaterally at the T13 – L1 junction, namely the spinal level that 
controls hind limb movement. In VEGF-injected animals alone, hind limb motor and sensory 
deficits consistently appeared at day two after surgery, but not at days 1 or 3 (onwards), as 
assessed by behavioural and locomotor tests (horizontal ladder test, walking treadmill, von 
Frey hair test, inclined plane, burrowing).  Histological examination revealed the presence 
of a blood-brain barrier leakage within the spinal cord as assessed by the presence of 
extravascular IgG and fibrinogen. Activated microglia/macrophages (ED1+, MHC class II+ and 
OX-42+ cells) were present at the injection site, peaking at day two, along with activated 
astrocytes. The mechanism responsible for the neurological deficit was investigated by 
attempting to antagonize specific VEGF signalling pathways, assessing a potential hypoxic 
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state using immunohistochemical techniques, and characterizing neuronal excitability by 
electrophysiological methods. 
 
VEGF injection provokes opening of the blood-brain barrier which is temporally and 
spatially associated with neuroinflammation and loss of function. The findings indicate a 
potential mechanism underlying loss of function in inflammatory neurological diseases such 
as MS.  
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Chapter I: Introduction 
 
Multiple sclerosis (MS) is an inflammation-mediated disease causing non-traumatic 
disability to 2.5 million people worldwide (Compston and Coles, 2002). This demyelinating 
disease was first described by Charcot in 1868 (Charcot, 1868) and is usually characterised 
by a biphasic course. 85% of cases begin with relapsing-remitting MS (RRMS) during which 
unpredictable relapses occur and are followed by periods of remission. 90% of these 
patients then switch, after about 25 years, to a secondary-progressive MS (SPMS) form, 
with a progressive and non-reversible neurological decline. 10% of patients undergo a third 
type of MS, primary-progressive MS (PPMS), with progressive decline from disease onset 
without recovery. Finally, 5% of patients have a steady progressive decline punctuated by 
acute attacks, called progressive relapsing MS (PRMS) (Weinshenker, 1996). A summary of 
the different courses of the disease observed in patients is provided in figure I.1. 
As described in this introduction, the aetiology of MS is complex and has not yet been 
elucidated. It is thought by many to involve an activation of auto-immunity against myelin 
proteins. It has traditionally been accepted that the symptoms are mainly due to 
dysfunction in axonal conduction arising from demyelination, but more recent studies 
suggest that inflammation may also be involved in the symptoms displayed during the 
relapses, and an energy deficit is thought to play a role. Attention has also focussed on 
alterations of the blood-brain barrier following the observation that this breakdown occurs 
as one of the first events in a new relapse. The aim of this study is to investigate whether 
breakdown of the blood-brain barrier plays a causative role in the production of 
neurological deficits in vivo.   
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I.1- Clinico-pathology of MS 
I.1.1- Relapses 
The appearance of new symptoms, called a relapse, is caused by neurological dysfunction 
which can be attributed to several different pathological events. 
 
I.1.1.1- Demyelination 
Demyelination is considered to be a primary cause of neurological deficits in MS patients. 
Loss of myelin exposes the axolemma and leads to conduction failure due to several 
mechanisms, including a deficit of sodium channels on this newly exposed part of the axon 
(Waxman et al., 1994; Waxman and Ritchie, 1993). The cause of the demyelination is not 
understood, but many believe that an immunological reaction is mediated by T-cells 
directly targeting myelin protein (Ben-Nun et al., 1996; Kerlero de Rosbo et al., 1993). 
Oligodendrocyte injury may also play a role in the demyelination phenomenon observed in 
MS (Patel and Balabanov, 2012). In MS lesions, oligodendrocytes express MHC-I molecules 
and are a potential direct target of the CD8+ T-cells (Hoftberger et al., 2004). Other factors 
such as inflammation and pro-inflammatory cytokines (Pouly et al., 2000; Vartanian et al., 
1995), oxidative injury (Thorburne and Juurlink, 1996) and excitotoxicity (McDonald et al., 
1998) also contribute to demyelination by affecting oligodendrocytes. 
 
I.1.1.2- Inflammation 
Generally, inflammatory cells such as macrophages, microglia or T lymphocytes are thought 
to be involved in the axonal injury observed in MS patients (Bitsch et al., 2000). 
Inflammatory cells enter the central nervous system (CNS) by crossing the blood-brain 
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barrier and can be deleterious by releasing cytokines. Inflammatory cytokines, such as 
tumour necrosis factor alpha (TNF-α) or interferon gamma (IFN-γ) have been reported to 
play a role in MS following the observation that increased levels of these cytokines 
correlated with the worsening of symptoms and exacerbation of pre-existing symptoms 
(Moreau et al., 1996). Pro-inflammatory cytokines can also provoke production of inducible 
nitric oxide synthase (iNOS), an inflammatory mediator thought to play a role in the 
neurological dysfunction observed in MS and experimental autoimmune encephalomyelitis 
(EAE), an animal model of MS (Bo et al., 1994; MacMicking et al., 1992; Willenborg et al., 
2007). Although demyelination has traditionally been thought to be the cause of loss of 
conduction, inflammation (Youl et al., 1991) and nitric oxide (Redford et al., 1997) have 
been shown to be sufficient to affect conduction properties on their own. 
 
I.1.1.3- Excitotoxicity 
In RRMS patients, an increase in CSF levels of glutamate and aspartate has been 
demonstrated in active lesions (Sarchielli et al., 2003) and MRI studies have confirmed 
these findings (Srinivasan et al., 2005). This increase in excitatory amino acid levels leads to 
an abnormal activation of ionotropic glutamate receptors (AMPA/kainate and NMDA 
receptors) and trigger an excessive influx of calcium in neurons and oligodendrocytes 
where these receptors are present, leading to neuronal degeneration (Arundine and 
Tymianski, 2003). Immunohistochemical studies show a correlation between axonal and 
oligodendrocyte damage and abnormal glutamate levels (Werner et al., 2001). Inhibition of 
glutamate receptors reduces neurological deficits in EAE (Wallstrom et al., 1996), probably 
by reducing axonal and oligodendrocyte damage (Pitt et al., 2000; Werner et al., 2000). 
Since oligodendrocytes play a major role in glutamate removal (Pitt et al., 2003), their 
destruction could further enhance glutamate’s deleterious effects.  
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I.1.2- Remission 
Between relapses, patients suffering from MS typically have periods of remission of 
variable length. The recovery of functions lost during a relapse occurs by several 
mechanisms, but perhaps most importantly by remyelination, which helps to restore 
conduction to (formerly) demyelinated axons. This process typically involves recruitment of 
oligodendrocyte precursor cells (Takahashi et al., 2013) which transform into 
oligodendrocytes that produce the myelin lipids and protein necessary for remyelination, 
enabling recovery of saltatory conduction (Nave and Trapp, 2008). Remyelination is not the 
only way to restore conduction. Resolution of inflammation has also been shown to 
correlate with recovery of function (Redford et al., 1997; Youl et al., 1991). Compensation 
by increasing the number of sodium channels has also been shown to restore conduction in 
demyelinated axons, allowing slower but effective conduction (Black et al., 1997). Finally, 
adaptive changes of the neural network may contribute to the disappearance of symptoms. 
Indeed, functional magnetic resonance imaging (fMRI) studies in MS patients (Cerasa et al., 
2006; Pantano et al., 2006) showed a reorganization of the functional activity of the brain 
by modifying the pattern of brain activation, recruiting for parallel pathways to compensate 
for the pathological impairments.  
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 Figure I.1: Evolution of disability with time for the different courses of disease observed in MS 
patients. RRMS: Relapsing remitting multiple sclerosis, PRMS: Progressive relapsing multiple 
sclerosis, PPMS: Primary progressive multiple sclerosis, SPMS: Secondary progressive multiple 
sclerosis. 
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I.1.3- Progression 
A relapsing/remitting phase of the disease may evolve into a progressive course in many 
patients. Others may experience a progressive course from the very beginning. Analysis of 
the CNS of such patients usually reveals areas of atrophy in both grey and white matter 
(Hofstetter et al., 2013). The permanent neurological deficit is thought to be caused by this 
atrophy rather than demyelination. 
 
I.1.4- Heterogeneity of lesions 
Pathological studies have revealed that different inflammatory components can play a role 
in demyelination (Lucchinetti et al., 2000) and axonal injury (Bitsch et al., 2000). Following 
this view, it has been proposed (Lucchinetti et al., 2000) that four different lesions patterns 
can be distinguished according to biopsy and autopsy results from patients with MS (Table 
I.1).  
 
Firstly, Pattern I has been attributed to T-cell- and macrophage-related inflammation. The 
presence of immunoglobulins and activated astrocytes indicates damage of the blood-brain 
barrier. Myelin proteins are degraded independently of their identity, contrary to another 
pattern (see below), and oligodendrocytes are lost in active lesions but seem to be present 
in inactive lesions, giving rise to the possibility of remyelination of inactive lesions. 
 
Pattern II is very similar to pattern I since it shares all the features described previously. The 
only difference is a stronger presence of immunoglobulins and the activation of 
complement, which can indicate a major role for immune activation. 
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Lesion 
Pattern 
Macrophage 
and T-cell 
inflammation 
Loss of 
oligodendrocytes 
Immunoglobulin 
presence 
Complement 
activation 
Loss of 
myelin 
proteins 
I Yes No Yes No All 
II Yes No Yes (strong) Yes All 
III Yes Yes (apoptosis) No No 
MAG 
only 
IV Yes 
Yes (not 
apoptosis) 
No No All 
Table I.1: Characteristics of the four main lesion patterns observed in MS patients, according 
to the classification of Lucchinetti and colleagues. 
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In Pattern III, the inflammatory infiltrate is still present but immunoglobulins and bound 
complement are not observed. However, preferential loss of myelin associated 
glycoprotein (MAG) occurs. At sites of MAG loss, a pronounced loss of oligodendrocytes is  
observed, mainly due to apoptosis (as indicated by presence of nuclear condensation and 
fragmentation (Cotter et al., 1990)). This preferential loss of MAG is associated with 
hypoxia-like tissue injury, indicated by production of hypoxia inducible factor-1α (HIF-1 α) 
(Aboul-Enein et al., 2003). 
 
In Pattern IV lesions, T-cells and macrophages constitute the main portion of the 
inflammatory infiltrate. Demyelination is present in conjunction with oligodendrocyte 
death which occurs through a non-apoptotic pathway. Finally, there is simultaneous 
degradation of all myelin proteins. 
 
I.1.5- Impairments of the motor system 
In MS patients, lesions often localize within the sensory-motor pathway, causing motor 
dysfunction. This can be not only the most visible deficit, but also the most common. 
Weakness of the limbs is often experienced by MS patients during relapses, most 
commonly affecting the lower limbs. Weakness is usually noticed only after exertion at 
first, but with time it may be present constantly.  
 
Spasticity is most often due to an amplification of motor reactivity to sensory stimulation, 
and results in hypertonia, an abnormally high muscle tone which confers unusual stiffness 
on muscles. Some patients also suffer from uncontrolled tremor (Alusi et al., 2001) in upper 
and lower limbs, and also in the trunk and head. Limb incoordination and gait ataxia is also 
a common feature of MS, resulting in clumsiness and poor balance. 
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I.2- The blood-brain barrier 
The concept of the blood brain barrier was discovered in the beginning of the 20th century 
by Ehrlich who noticed that when injecting intravenously a range of dyes, staining was 
present in all tissue but the brain (Ehrlich, 1904). One of his students later confirmed his 
suspicion by injecting the same dyes into the cerebrospinal fluid (CSF) and observing that 
the dyes did not enter the blood flow (Goldmann, 1913). 
 
I.2.1- Structure  
The primary role of the blood brain barrier is to prevent plasma components, red blood 
cells and most leukocytes from entering the brain where they could be deleterious 
(Zlokovic, 2008). It also maintains the biochemical environment of the CNS necessary for its 
normal functioning, especially synaptic transmission. The barrier is mainly created by 
endothelial cells all along the capillaries in the brain and spinal cord (Abbott et al., 2010). 
Another interface is present at the epithelial cells of the choroid plexus, constituting the 
blood-cerebrospinal fluid barrier (Brown et al., 2004). Finally, the avascular arachnoid 
epithelium constitutes another barrier separating the extracellular fluid of the body from 
the central nervous system (Abbott et al., 2006). The paragraphs below will focus on the 
blood-brain barrier created by endothelial cells. 
 
I.2.1.1- Cellular junctions 
The blood brain barrier consists at the level of the vasculature of a monolayer of brain 
endothelial cells that are sealed together in order to prevent free exchange of solutes 
between the blood and the brain (figure I.2) (Brightman and Reese, 1969; Reese and 
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Karnovsky, 1967). This interface is characterised by a low paracellular permeability and high 
electrical resistance (Zlokovic, 2008), and it is achieved by cellular junctions between the 
brain endothelial cells that prevent free transfer of molecules between the blood and the 
brain. Indeed, only molecules smaller than 400 Da with less than nine hydrogen bonds can 
freely cross the blood-brain barrier (Pardridge, 2007). These cellular junctions consist of 
tight junctions, adherens junctions and proteins linking these junctions to the endothelial 
cell cytoskeleton.   
 
Tight junctions 
Tight junction proteins help to form a continuous membrane between the blood and the 
brain. The first to be discovered was occludin (Furuse et al., 1993), a 65 kDa integral 
membrane protein made of two extracellular domains. Whereas tight junctions in occludin-
deficient mice do not seem to be altered at the ultrastructural level (Saitou et al., 2000), 
calcification of the brain is observed in these mice. It has also been shown that 
phosphorylation of occludin at the tight junction complex (Sakakibara et al., 1997) 
regulates permeability independently of changes in the cytoskeleton (Hirase et al., 2001). 
These observations suggest that occludin regulates, rather than contributes to, blood-brain 
barrier properties.  
 
Claudins are a family of 23 kDa integral membrane proteins responsible for sealing of the 
blood-brain barrier (Furuse et al., 1998) through the interaction of their extracellular loops 
(Piontek et al., 2008). Claudin-3, -5 and -12 are localized in the brain (Nitta et al., 2003; 
Zlokovic, 2008) and prevent the leakage of molecules in a size-specific manner; for 
instance, claudin-5 deficiency in mice allow the diffusion of molecules smaller than 800 Da 
(Nitta et al., 2003).  
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Other proteins, called adhesion molecules, are also present in tight junction complexes. 
The junctional adhesion molecule family (JAM) plays a role via homophilic and heterophilic 
interactions (Bazzoni et al., 2000a; Wolburg and Lippoldt, 2002). These 40 kDa 
transmembrane proteins are involved in leukocyte recruitment into the brain (Del Maschio 
et al., 1999), and in organizing the intercellular structure via the interaction with occludin 
(Bazzoni et al., 2000b).  
 
Finally, an endothelial cell-selective adhesion molecule (ESAM) has been found in 
endothelial cells (Nasdala et al., 2002) but its role in the tight junctional structure is still 
poorly understood. 
 
Adherens junctions 
Adherens junctions are expressed between brain endothelial cells (Schulze and Firth, 1993) 
and are responsible for adhesion between endothelial cells, as well as the regulation of 
permeability.  
 
VE-cadherin is the main component of adherens junction proteins and is responsible for 
cell-cell adhesion via its extracellular loops (Vincent et al., 2004) via homophilic binding 
(Breviario et al., 1995). The cytoplasmic part is linked to the actin cytoskeleton by catenins 
(Knudsen et al., 1995) which stabilize the protein in the cell-membrane, because truncated 
molecules without links to actin do not promote adhesion nor control permeability 
(Breviario et al., 1995). VE-cadherins are also involved in angiogenesis and maintenance of 
blood vessels (Lampugnani and Dejana, 2007).  
 
Platelet endothelial cell adhesion molecule 1 (PECAM-1 or CD31) is present on endothelial 
cells but outside the tight junction complex. It has been shown to play a role in lymphocyte 
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infiltration in the brain; the use of a soluble form of PECAM-1 impairs lymphocytes entry 
and diminishes the severity of symptoms in EAE mice (Reinke et al., 2007). 
Cytoskeleton links 
Tight junction and adherens junction proteins are linked to the cytoskeleton of endothelial 
cells by cytoplasmic accessory proteins (Hawkins and Davis, 2005). Proteins of the zonula 
occludens (ZO) family have been shown to interact with tight junction (Stevenson et al., 
1986) and adherens junction proteins (Itoh et al., 1993). ZO-1 (220 kDa) is involved in the 
tight junction communication with the actin cytoskeleton (Fanning et al., 1998) and 
alteration in ZO-1 cellular localization correlates with inter-cellular permeability (Fischer et 
al., 2002). ZO-2 is thought to have a redundant function with ZO-1 as it is similarly 
distributed (Gumbiner et al., 1991) and can replace it to form normal tight junctions in 
cultured epithelia lacking ZO-1 (Umeda et al., 2004). Finally, ZO-3 is also present (Hawkins 
and Davis, 2005) but its function remains poorly understood.  
 
I.2.1.2- The neurovascular unit 
Several specialized cells communicate with the brain endothelia and form the 
neurovascular unit (Abbott et al., 2006). These cells are pericytes, astrocytes and microglia. 
Their close proximity to endothelial cells allows paracrine regulations (Lok et al., 2007).  
 
Pericytes 
Pericytes wrap the endothelium with their processes and, along their cytoplasmic 
processes that encircle 30% to 70% of the capillary wall (Zlokovic, 2008), they communicate 
directly with endothelial cells through specialized synapses (Bell and Zlokovic, 2009). At 
points of contact, which are functionally determined, tight junctions and adherens 
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junctions are present (Allt and Lawrenson, 2001). They are involved in microvessel stability 
in a mechanical manner (von Tell et al., 2006) but also by promoting endothelial cell 
differentiation and quiescence (Armulik et al., 2005). Pericytes also control the formation 
of tight junctions (Daneman et al., 2010), guide endothelial cells during developmental 
angiogenesis (Virgintino et al., 2007), and their contractile properties allow for the 
regulation of capillary blood flow (Peppiatt et al., 2006). 
 
Astrocytes 
The endfeet of astrocytes make contacts with other cells in the neurovascular unit (figure 
I.2), which is important in the regulation of the extracellular electrolyte concentration. 
Their perivascular endfeet express the water channel aquaporin-4 (Nielsen et al., 1997) and 
the potassium channel Kir 4.1 (Takumi et al., 1995) and contribute to water volume and 
electrolyte regulation. For example, blood-brain barrier disruption leads to overexpression 
of aquaporin-4 receptors in perivascular astrocytes presumably to limit oedema formation 
(Tomas-Camardiel et al., 2005). They also secrete factors able to modify the blood-brain 
barrier phenotype in vitro by reducing angiogenesis (Lee et al., 2003), and promote 
maturation of the blood brain barrier via formation of tight junctions induced by glial 
derived neurotrophic factor (Igarashi et al., 1999). Astrocytes also contribute to 
neurovascular coupling by adapting cerebral blood flow to the neural metabolic demand, 
as photolysis of caged Ca2+ in astrocytic endfeet leads to vasodilation (Anderson and 
Nedergaard, 2003). Moreover, inhibition of astrocytic metabotropic glutamate receptor-
mediated Ca2+ oscillations reduces the vasodilation induced by an increase in neural activity 
both in vitro and in vivo (Zonta et al., 2003).  
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Figure I.2: Cellular organisation of the blood-brain barrier. 
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Microglia 
Microglia connect with the brain endothelial cells by making endfeet connections and 
forming the glia limitans with astrocytes (figure I.2), which constitutes the barrier against 
mononuclear cell infiltration into the brain (Man et al., 2007). The perivascular microglial 
cells, endogenous to the CNS, are derived from bone marrow (Hickey and Kimura, 1988) 
and present antigens to infiltrating lymphocytes.  Microglia also communicate with the 
blood brain barrier via cytokines and chemokines in order to allow the recruitment by the 
CNS of peripheral mononuclear cells by a process of diapedesis through the cytoplasm of 
endothelial cells rather than a paracellular route (Abbott et al., 2010). The role of microglia 
in the breakdown of the blood-brain barrier is discussed below.  
 
Basal lamina 
Finally, astrocytes and pericytes are separated from the brain endothelia by the basal 
lamina (figure I.2) (Zlokovic, 2008). This membrane is made of matrix proteins such as 
collagen and laminin and provides mechanical support for the neurovascular unit (Desai et 
al., 2007). The neurovascular unit cells all express matrix adhesion receptors (Del Zoppo et 
al., 2006), such as the integrin family which regulates endothelial cell migration and vessel 
formation during angiogenesis (del Zoppo and Milner, 2006). 
 
I.2.2- Function 
I.2.2.1- Ion balance 
The blood brain barrier regulates the ion concentration in the CSF thanks to specific ion 
channels and transporters in order to maintain the optimal synaptic activity. For instance, 
the concentration of potassium in the CSF is maintained at 2.5-2.9 mM independently of 
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the variations in concentration in plasma (approximately 4.5 mM) (Hansen, 1985). The 
sodium pump (Na+-K+-ATPase) regulates the sodium and potassium gradients at the 
abluminal membrane (Zlokovic, 2008) while, at the luminal membrane, the Na+-K+-2CL- co-
transporter is responsible for the entry of potassium, sodium and chloride into the brain 
(O'Donnell et al., 2004). Intracellular pH control is performed via sodium-hydrogen 
exchangers expressed at the luminal surface, and chloride-bicarbonate exchangers present 
on both sides of the barrier (Taylor et al., 2006). Other ions such as Ca2+, Mg2+ are also 
regulated at the blood brain barrier (Jeong et al., 2006; Nischwitz et al., 2008). 
 
I.2.2.2- Neurotransmitters 
Glutamate, a neuroexcitatory amino acid, is present in high concentration in the blood and 
its level varies significantly after ingestion of food (Abbott et al., 2010). Three excitatory 
amino acid transporters (EAAT-1, 2 and 3) are localized at the blood brain barrier and are 
responsible for glutamate and aspartate homeostasis. Depending on the extracellular level 
of glutamate, influx or efflux of glutamate occurs. For example, the systemic use of a 
glutamate scavenging agent, which reduces the glutamate level in the blood, leads to efflux 
of glutamate from the brain and reduces excitotoxicity after brain injury (Zlotnik et al., 
2007). The blood brain barrier thus prevents its release into the CNS in an uncontrolled 
manner and subsequent neurotoxic damage. In this way the barrier allows keeping the 
central and peripheral neurotransmitter pools separated (Bernacki et al., 2008).  
 
I.2.2.3- Macromolecules 
Specific peptide and protein transporters, mainly peptide transport system proteins (PTS), 
are also present at the blood-brain barrier. PTS-1 and -2 are located at the abluminal 
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surface and are responsible for efflux of enkephalins (Banks and Kastin, 1997) and arginine-
vasopressin (Banks et al., 1987) respectively from the brain. PTS-3 transports peptide T into 
the brain (Barrera et al., 1987) and PTS-4 can transport macromolecules bi-directionally 
(Barrera et al., 1991).  
 
Receptor-mediated transport systems are responsible for transfer of larger molecules such 
as transferrin (Jefferies et al., 1984) or insulin (Pardridge et al., 1985). The characteristics of 
this receptor-mediated transport can be used for drug delivery: agents that normally do 
not get into the brain can be conjugated to antibodies against a blood-brain barrier 
receptor which act as a ligand and allow the crossing of the agent.  
 
Finally, the blood brain barrier prevents macromolecules from the plasma to enter the CNS 
where they are usually absent. Several individual plasma proteins and their actions on the 
CNS are described in detail below. 
 
I.2.2.4- Neurotoxins 
Neurotoxins (whether they are endogenous metabolites, proteins or xenobiotics) may have 
a deleterious effect on the neuronal population, which is especially significant because 
neurons are deprived of significant regenerative capacity. Several adenosine triphosphate 
(ATP)-binding cassette transporters are located at the blood brain barrier and are able to 
pump these neurotoxic substances out of the CNS (Abbott et al., 2010). On the other hand, 
these transporters also play a role in drug resistance, since they are able to transport brain-
targeted drugs out of the brain. For instance, the multidrug resistance transporter P-
glycoprotein (P-gp) is expressed at the luminal surface of endothelial cells and removes 
toxic metabolites, mainly cationic drugs (Loscher and Potschka, 2005). Knock-out studies in 
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mice have shown that a deficiency in P-gp leads to enhanced neurotoxicity of brain-
targeted drugs (Schinkel et al., 1994; Schinkel et al., 1996), indicating that drug removal is a 
defence mechanism in the first place. The multidrug resistance-associated proteins (MRP) 
can be expressed on both the abluminal and luminal surface and are mainly responsible for 
anionic compound removal (Loscher and Potschka, 2005). 
 
I.2.2.5- Brain nutrition 
Specific transporter proteins are expressed at the blood brain barrier to allow nutrients and 
metabolites required by the CNS to reach it (Abbott et al., 2006). Specific carrier-mediated 
transporters allow nutrients such as glucose (Simpson et al., 2007), monocarboxylic acids  
(lactate, pyruvate) (Simpson et al., 2007), amino acids (Hawkins et al., 2006) and vitamins 
(Spector and Johanson, 2007) to enter the brain. Some of these transporters are polarised 
and can be specifically expressed at the luminal or abluminal surface of endothelial cells, 
thus allowing for a unique direction of transport (blood to brain or brain to blood) (Ohtsuki 
and Terasaki, 2007). For example, the glucose transporter GLUT-1 is expressed exclusively 
at the blood brain-barrier with a higher concentration at the abluminal surface (Simpson et 
al., 2007), preventing accumulation of glucose in the brain.  
 
I.2.3- Breakdown of the blood-brain barrier in MS 
Several studies suggest that breakdown of the blood-brain barrier plays a role in disorders 
involving neuroinflammation such as MS, Alzheimer’s disease (AD) or Parkinson’s disease 
(PD) (Leech et al., 2007; Miyakawa, 2010; Stolp and Dziegielewska, 2009). It is still unclear 
whether these alterations are a causal event, or a consequence of these pathologies.  
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The development of imaging techniques like magnetic resonance imaging (MRI) have 
allowed the dysfunction of the blood-brain barrier to be assessed in MS patients. 
Gadolinium diethylenetriaminepenta-acetate (Gd-DTPA) enhancement MRI techniques 
have been developed in the past two decades and are commonly used for detection of 
leakage of the blood-brain barrier in MS patients. Enhancement is consistently found within 
new lesions in patients suffering from relapsing/remitting MS and secondary progressive 
MS (Kermode et al., 1990). Because of this early permeability in MS lesions, it has been 
suggested that leakage of plasma into the CNS may have a role in lesion formation (Cotton 
et al., 2003; Kermode et al., 1990). Moreover, there is a strong correlation between the 
duration of Gd-DTPA enhancement and the size and severity of the lesion formed in the 
area where the breakdown occurred. Tight junction abnormalities (occludin, ZO-1) have 
also been associated with lesion formation, leakage of the blood-brain barrier and 
demyelination in MS patients (Kirk et al., 2003; Plumb et al., 2002). 
 
In animal models of MS, breakdown of the blood-brain barrier is also present. In EAE, the 
leakage occurs at the early onset of neurological deficit, persists during the peak of the 
disease and disappears at recovery (Floris et al., 2004). Also, the leakage correlates with the 
duration and severity of neurological signs (Proescholdt et al., 2002b). Correspondingly, Gd-
DTPA enhancement in EAE lesions is associated with relapses, and the duration of the 
leakage correlates with the expression of symptoms (Hawkins et al., 1991). These 
observations suggest that leakage of the blood-brain barrier is directly implicated in the 
neurological deficits observed in neuroinflammation (Fabis et al., 2007; Floris et al., 2004; 
Hawkins et al., 1991). 
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I.2.4- Breakdown of the blood-brain barrier and inflammation 
In most neuroinflammatory diseases, and particularly in MS, alteration of the blood-brain 
barrier and inflammation are often linked. It has been shown that leukocytes are able to 
enter the CNS not only via small gaps at intercellular cell junctions, but also via a 
transcellular pathway through endothelial cells (Engelhardt and Wolburg, 2004). In MS 
lesions, the breakdown of the blood-brain barrier is associated with infiltration of activated 
neutrophils, lymphocytes and monocytes (Petty and Lo, 2002). It has also been 
demonstrated that in knock-out mice lacking pro-inflammatory mediators, EAE still induced 
a breakdown of the blood-brain barrier but less severely than in wild type mice, suggesting 
that the breakdown of the blood-brain barrier is at least partly mediated by inflammation 
(Fabis et al., 2007). A direct correlation has also been made between the disruption of the 
blood-brain barrier and the localization of inflammatory infiltration sites in mice with EAE 
(Muller et al., 2005). 
 
Products of inflammatory cells such as cytokines and chemokines have the ability to induce 
alterations of the blood-brain barrier. In rats intra-cranially injected with interleukin-1β (IL-
1β), the increased permeability observed a few hours following injection was dependent on 
the presence of neutrophils within the CNS (Blamire et al., 2000). In EAE, an increase in IL-1 
and TNF-α release has been demonstrated and correlated with the observed alterations of 
the blood-brain barrier (Abraham et al., 1996; Gijbels et al., 1990). Other interleukins (IL-2 
and IL-6) have also been shown to induce permeability (Saija et al., 1995). 
 
Finally, inflammatory cells and their mediators can have a direct effect on the expression of 
tight junction proteins, either at a post-transcriptional level (Bennett et al., 2010) or by 
directly inducing their degradation (Kniesel and Wolburg, 2000), thus contributing to an 
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enhanced permeability. Leukocyte infiltration has also been reported to alter the 
organization of tight junctions (Bolton et al., 1998), reducing the expression of occludin and 
ZO-1. Also, TNF-α and IFN-α released by lymphocytes can decrease the occludin gene 
promoter activity and reduce occludin mRNA expression in epithelial cells (Mankertz et al., 
2000). 
 
From the evidence gathered, it is clear that inflammation and the blood-brain barrier are 
intimately related. However, the mechanism by which this relationship is established is yet 
to be fully revealed, as well as the sequence of events. Discerning the cause from the 
consequences is currently the source of many controversies. 
 
I.3- Plasma components in the CNS 
I.1.1- Fibrinogen 
Fibrinogen is a 340 kDa glycoprotein present in blood and playing a role in the coagulation 
cascade. After the conversion to fibrinogen monomers by thrombin, it polymerizes to form 
fibrin. Fibrinogen only reaches tissue in the case of injury, being found only in blood under 
normal conditions. CNS cells have been shown to express activators of the coagulation 
cascade that trigger the thrombin-mediated transformation of fibrinogen to fibrin (Smiley 
et al., 2001). In neuroinflammatory conditions, such as within the lesions in MS patients, 
fibrinogen is present around the blood vessels where it colocalizes with mononuclear cells 
(Sobel and Mitchell, 1989) in both acute and chronic MS lesions (Kirk et al., 2003). In 
pattern III lesions (as described by Lucchinetti and colleagues (Lucchinetti et al., 2000)), 
fibrinogen binds to nodes of Ranvier and activates microglia probably through toll-like 
receptor 4 (TLR-4) receptor- or cluster of differentiation 11b (CD11b) receptor-signalling, 
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and it promotes the release of pro-inflammatory cytokines (Adams et al., 2007; Flick et al., 
2004a; Perez et al., 1999; Smiley et al., 2001). In particular, fibrinogen can induce a 
phagocytic phenotype in microglia (Adams et al., 2007), and this activation occurs before 
the onset of demyelination (Marik et al., 2007). Similar observations are made in animal 
models. The mouse transgenic line TgK21, a TNF-α mouse model of MS, presents the same 
features described above regarding fibrinogen; deposition is present before tissue damage 
and correlates with sites of demyelination (Akassoglou et al., 2004). Genetic and 
pharmacological depletion of fibrinogen in this mouse model leads to a decreased 
inflammation and a later onset of demyelination (Akassoglou et al., 2004). Fibrinogen plays 
a role in the adhesion and infiltration of inflammatory cells such as leukocytes, neutrophils 
and macrophages (Flick et al., 2004b; Whitlock et al., 2000). Fibrinogen can also trigger the 
formation of astrocytic scars and prevent CNS repair following injury (Schachtrup et al., 
2010). Regarding alterations of the blood-brain barrier, depletion of fibrinogen in animal 
models of AD has been shown to reduce permeability and Evans blue leakage (Paul et al., 
2007). As a consequence, fibrinogen’s interaction with the different cells present in the CNS 
may have consequences in neuroinflammatory pathologies. 
 
I.2.2- Thrombin 
Thrombin is a 70 kDa serine-proteinase involved in the coagulation cascade. Particularly, it 
catalyses the conversion of fibrinogen to fibrin. In the cell, thrombin signals through G-
coupled protein protease-activated receptors (PAR). PARs are normally expressed in the 
CNS of rats and humans, on neurons and glial cells (Sokolova and Reiser, 2008).  
 
In neuroinflammation, thrombin has been shown to play a role in the induction of the 
inflammatory process. Thrombin can trigger microglial activation leading to proliferation 
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and cytokine release (Dheen et al., 2007; Moller et al., 2000) and nitric oxide production 
(Lee da et al., 2006; Sokolova and Reiser, 2008). In vivo injection of thrombin in the brain 
results in microglial activation and oxidative and nitrative stress induced by the expression 
of inducible nitric oxide synthase (iNOS) (Choi et al., 2005b). Thrombin has also been shown 
to interact with astrocytes and induce nitric oxide production (Meli et al., 2001). PAR 
receptors have been shown to be upregulated on astrocytes and microglia in EAE, 
suggesting a potential mechanism for thrombin-induced glial cell activation (Bushell, 2007). 
Thrombin is also implicated in neurodegeneration, depending on its concentration within 
the CNS. It has been demonstrated that in ischaemia, low concentrations of thrombin can 
be neuroprotective whereas high concentrations are neurotoxic in a dose-dependent 
manner (Lee da et al., 2006; Striggow et al., 2000). Direct injection of thrombin in the CNS 
results in neurodegeneration in vivo (Lee da et al., 2006). Moreover, inhibition of microglial 
activation by thrombin protects neurons against this degradation (Choi et al., 2005a). 
Attenuation of thrombin has also been shown to be neuroprotective in rat models of 
injured optic nerve, highlighting a deleterious effect of thrombin on axons.  
 
Thrombin can also play a role in alterations of the blood-brain barrier as it can promote 
monocyte migration and increased permeability of endothelial cells by inducing release of 
platelet activating factor, an inflammatory transmitter and vasodilator (Nagy et al., 1995; 
Strukova, 2001). 
 
I.3.3- Albumin 
Albumin is a major plasma protein of 66 kDa, accounting for 50% of all plasma proteins 
(Hooper et al., 2005b). Similarly to thrombin and fibrinogen, it may play role in the 
neuroinflammatory process, being normally kept out of the CNS by the blood-brain barrier. 
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It has been shown that in EAE, an influx of albumin occurs at the lesion site where the 
blood-brain barrier becomes permeable (Butter et al., 1991). Albumin entry into the CNS is 
able to induce microglial activation and proliferation (Hooper et al., 2005a), resulting in the 
release of pro-inflammatory cytokines such as TNF-α and IL-1β (Zhao et al., 2009). Albumin 
also triggers the release of superoxide by microglia (Nakamura et al., 2000) and the 
induction of iNOS, leading to the production of NO (Hooper et al., 2009). In astrocytes, 
albumin can cause activation and proliferation (Nadal et al., 1995), and has consequences 
on neuronal excitability, discussed below. All these interaction can have deleterious effects 
on the neuronal population. Indeed, activation of microglia by albumin is correlated with 
neuronal damage and apoptosis (Hooper et al., 2009). 
 
I.4- Hypoxia 
I.4.1- CNS perfusion 
The CNS is particularly vulnerable to hypoxia and defects in oxygen supply. It is thought to 
consume 15% of the cardiac output, 20% of the oxygen and 10% of the glucose consumed 
by the whole body (Afifi, 2005; McKenna, 2006), the two forms of energy consumed by the 
brain. People lose consciousness within seconds of blood flow interruption and undergo 
irreversible damage within minutes (Hansen, 1985). 
 
In other tissues of the body, glycogen stores are present in order to cope with periods of 
high energy demand when oxygen provided by the blood supply is not enough to sustain 
the energy metabolism. In the brain this store is present in astrocytes (Cataldo and 
Broadwell, 1986) and is used during periods of hypoglycaemia (Suh et al., 2007). However, 
in vivo studies in ischaemia have shown that this glycogen store is unable to compensate 
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for the lack of energy substrate as it is rapidly depleted. As a consequence, the brain is 
exposed to damage even during short periods of interruption of energy supply.  
 
I.4.2- Potential role of hypoxia in MS 
MS is generally thought to be an immune mediated disease, where the immune system 
wrongly attacks myelin proteins. However, breakdown of the blood-brain barrier occurs 
before the onset of demyelination in some patients, suggesting that another mechanism 
may be responsible for lesion formation. Lucchinetti and colleagues (Lucchinetti et al., 
2000) categorized the lesions observed in MS patients and distinguished one subtype, 
pattern III lesions, that were characterized by loss of myelin with almost no T-cell or B-cell 
infiltration: a similar lesion has been described in detail by Prineas and colleagues (Barnett 
and Prineas, 2004). A similar pattern of lesion has also been observed in brain ischemic 
insults such as stroke (Aboul-Enein et al., 2003), suggesting that hypoxia is responsible for 
the loss of myelin observed. Also, hypoxia can cause an increase in permeability of the 
blood-brain barrier (Dux et al., 1984), thus providing a potential origin of the leakage 
observed in early MS lesions. Moreover, a reduced cerebral blood flow has been observed 
in the brain of patients suffering from MS (Adhya et al., 2006; Law et al., 2004) and areas 
weakly perfused have been correlated with lesion formation in the white matter, with axon 
sparing and microglial activation in rats (Farkas et al., 2004). Finally, a higher probability of 
lesion formation in patients is linked to white matter area with lower perfusion rates 
(Holland et al., 2012).  
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I.4.3- Markers of hypoxia 
In this report, we used two different methods to detect hypoxia in spinal cord tissue. Both 
were using specific markers, namely HIF and pimonidazole, which are endogenous and 
exogenous respectively. The mechanisms of hypoxia detection by these markers are 
described below.  
 
I.4.3.1- HIF-1α 
HIF-1 is a heterodimer consisting of HIF-1α and HIF-1β. HIF-1β is constitutively expressed 
and located in the nucleus whereas HIF-1α is oxygen sensitive. Both subunits are 
continuously transcribed and translated but under normal oxygen conditions the HIF-1α 
subunit is hydroxylated in an oxygen dependant manner by proxyl hydroxylate enzymes 
(Schofield and Zhang, 1999). The hydroxylated subunit is then recognised by the von 
Hippel-Lindau (VHL) protein which targets it for proteasomal degradation (Maxwell et al., 
1999). Another protein, factor-inhibiting HIF, is also able to hydroxylate it and reduce HIF 
activity (Lando et al., 2002). Under hypoxia, however, HIF-1α is not recognized by VHL and 
is therefore not targeted for degradation. It is thus allowed to enter the nucleus and 
dimerize with HIF-1β to promote transcription of hypoxia response elements (HRE) 
(Klimova and Chandel, 2008). HIF-1α is therefore a potent marker of hypoxic condition in 
cells.  
 
I.4.3.2- Pimonidazole 
Pimonidazole is a 2-Nitroimidazole molecule which binds to proteins and accumulates in 
cells under hypoxic conditions. In the presence of adequate oxygen concentration, it is 
oxidized to pimonidazole N-oxide or conjugated via glucoronyl transferase or 
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sulfotransferase. These products are then readily metabolized and excreted. On the other 
hand, oxygen competes with nitroreductases to provide the first electron needed to reduce 
pimonidazole. Hence, in low oxygen conditions, pimonidazole is reduced to a 
hydroxylamine which can then irreversibly bind the –SH group of proteins or glutathione 
and accumulate in the tissue. The bound pimonidazole can then be detected via 
immunohistochemical techniques and used as a hypoxia marker (figure I.3) (Arteel et al., 
1998).  
 
I.4.3.3- Correlation between pimonidazole and HIF-1α labelling 
Hutchison and colleagues (Hutchison et al., 2004) compared the viability of both 
pimonidazole and HIF-1α as markers of hypoxia by performing a correlation study in 
tumour tissue. They found a weak but significant correlation between pimonidazole and 
HIF-1α staining and only a weak link between high HIF-1α and oxygen concentration 
measured with oxygen electrodes. This is at odds with another study showing a strong 
correlation between HIF-1α labelling and oxygen concentration (Haugland et al., 2002). 
Some variability in HIF-1α labelling following hypoxia is therefore present. One potential 
reason explaining this discrepancy is the fact that HIF-1α labelling only detects strong 
hypoxia and is therefore not useful for milder situations (Haugland et al., 2002). Another  
possible reason is that, whereas pimonidazole is a hypoxia-specific marker, HIF-1α 
degradation is regulated by mechanisms other than hypoxia such as the 
phosphatidylinositol 3’-kinase (PI3K) pathway involving growth factors (Zhong et al., 2000). 
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Figure I.3: Schematic representation of pimonidazole metabolism in hypoxic and non-
hypoxic tissue 
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I.5- Vascular endothelial growth factor 
I.5.1- The protein and its receptors 
Vascular endothelial growth factor (VEGF) was first discovered in 1983 as a vascular 
permeability factor (VPF) (Senger et al., 1983) and was then rediscovered as an endothelial 
cell mitogen later (Ferrara and Henzel, 1989). It is a homodimeric glycoprotein responsible 
for blood vessel development and angiogenesis. Five members compose the VEGF family in 
mammals: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PLGF). Two 
proteins are structurally related: the parapoxvirus Orf VEGF (VEGF-E) and the snake venom 
VEGF (VEGF-F). VEGF-A is a 46kDa protein and exists in six different isoforms, coming from 
different splicing: VEGF-A121, VEGF-A 145, VEGF-A 165, VEGF-A 183, VEGF-A 189 and VEGF-A 206. 
VEGF-A165, named VEGF in this report, is the most abundant form while VEGF-A 145 and 
VEGF-A 206 are rare (Robinson and Stringer, 2001). In mice and rats, VEGF isoforms lack a 
glycine residue and are therefore one amino acid shorter than the human protein. A broad 
range of cells are able to produce VEGF, including vascular smooth muscle cells, 
macrophages and tumour cells (Berse et al., 1992). 
 
VEGF can bind to three different tyrosine kinase receptors (VEGFR-1, VEGFR-2 and VEGFR-
3), each being expressed by specific cell types and therefore mediating different biological 
functions (Holmes et al., 2007). A summary of VEGF receptors and their specific ligands is 
provided in figure I.4. Upon binding of one of the possible ligands, VEGFRs form either 
homodimers or heterodimers. Dimerization of receptors leads to the activation of the 
kinase activity resulting in autophosphorylation. Recruiting of second messengers follows 
with the activation of the ligand-specific signalling pathway (Olsson et al., 2006).  
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I.5.1.1- VEGFR-1 
VEGFR-1 is a high affinity receptor for VEGF-A, VEGF-B and PLGF of 180 kDa. It is expressed 
on endothelial cells and is involved in endothelial cells migration (Kanno et al., 2000). These 
biological activities are thought to occur only in presence of VEGFR-2 as when cross-talk 
with VEGFR-2 is prevented, VEGFR-1 activation is not capable to promote these responses 
(Rahimi, 2006). VEGFR-1 may therefore act as a trap for VEGF, regulating VEGFR-2 function 
by controlling VEGF availability. However, when VEGFR-1 is able to heterodimerize with 
VEGFR-2, it can promote angiogenesis. At the vascular level, it also enhances VEGFR-2 
induced permeability (Takahashi et al., 2004). VEGFR-1 is also expressed on other cell types 
such as macrophages and monocytes (Sawano et al., 2001) where it has been shown to 
mediate their migration (Barleon et al., 1996; Hiratsuka et al., 1998) and reduce the 
production of pro-inflammatory cytokines by macrophages (Autiero et al., 2003). It can also 
induce the recruitment of haematopoietic stem cells for reconstitution of hematopoiesis 
(Hattori et al., 2002). 
 
I.5.1.2- VEGFR-2 
VEGFR-2 is a 200 kDa protein to which VEGF-A, VEGF-C, VEGF-D and VEGF-E can bind. VEGF 
has an affinity for VEGFR-2 approximately 10-fold lower than for VEGFR-1 but the triggered 
kinase activity is much stronger following VEGFR-2 activation (Takahashi and Shibuya, 
2005). VEGFR-2 is found mainly at the surface of vascular endothelial cells but is also 
present on neuronal cells and hematopoietic stem cells. VEGFR-2 is responsible for the 
migration, proliferation and survival of vascular endothelial cells but also vascular 
permeability (Holmes et al., 2007). VEGFR-2 specific agonists are able to increase 
permeability on their own (Hillman et al., 2001) and specific inhibition of VEGFR-2 prevents 
VEGF-induced permeability (Whittles et al., 2002), confirming the essential role of VEGFR-2. 
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I.5.1.3- VEGFR-3 
VEGFR-3 is a 195 KDa receptor specific for VEGF-C and VEGF-D expressed on lymphatic 
endothelial cells (Takahashi and Shibuya, 2005). It is thought to be important during 
embryonic development for migration and sprouting for endothelial lymphatic precursor 
cells (Olsson et al., 2006). It has been shown that a VEGFR-3 specific mutant of VEGF-C is 
able to induce lymphangiogenesis in mice without any influence on blood vessels (Veikkola 
et al., 2001). 
 
I.5.1.4- Neuropilin 1 and 2 
Neuropilin-1 (NRP-1) is a 140 kDa cell surface glycoprotein involved in neuronal guidance 
via semaphorin signalling. NRP-1 also binds VEGF-A165, VEGF-B, PLGF and some VEGF-E 
variants and NRP-2 binds VEGF-A165, VEGF-A145, PLGF and VEGF-C (Takahashi and Shibuya, 
2005). The very short intracellular domain of NRPs prevents any biological activity upon 
VEGF binding. However, the proliferation and migration of endothelial cells induced by 
VEGF binding to VEGFR-2 is enhanced in presence of NRP-1 (Soker et al., 1998), suggesting 
that NRP-1 acts as an enhancer of VEGFR-2 signalling by forming a complex with it 
(Whitaker et al., 2001). Similarly, NRP-2 seems to play a regulating role in VEGF induced 
lymphatic development (Yuan et al., 2002). 
 
I.5.2- VEGF-induced permeability mechanism 
The mechanism by which VEGF induces permeability has not yet been fully elucidated. 
However, signalling through VEGFR-2 is required for both angiogenesis and permeability. 
VEGF-E, which binds to VEGFR-2 but not VEGFR-1 is able to induce angiogenesis without 
sign of plasma leakage, suggesting that the combined action of VEGFR-1 is required for 
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permeability to occur (Kiba et al., 2003). NO has been shown to be a mediator of vascular 
angiogenesis and permeability (Fukumura and Jain, 1998) and VEGF receptor activation 
leads to activation of endothelial nitric oxide synthase (eNOS) via activation of 
phospholipase C-γ activation and calcium influx or via phosphorylation of eNOS by 
AKT/protein kinase B (Bates and Harper, 2002; Fulton et al., 1999). Several studies have 
confirmed this observation. VEGF has been shown to induce eNOS and inducible nitric 
oxide synthase (iNOS) in vitro through VEGFR-2 activation (Kroll and Waltenberger, 1999) 
and studies in knock-out mice showed that VEGF induced permeability was suppressed in 
eNOS deficient mice, confirming that eNOS plays an important role in permeability 
(Fukumura et al., 2001). Moreover, a selective eNOS inhibitor, cavtratin, has recently been 
used to reduce both breakdown of the blood-brain barrier and the severity of lesions in 
mice with EAE (Argaw et al., 2012). 
 
I.5.3- Activity of VEGF in the CNS 
Although the predominant role of VEGF is related to the regulation of angiogenesis, several 
studies have shown that VEGF can also have direct effects on the CNS. While most of these 
effects seem to have a positive impact on neurons and other cells composing the CNS, a 
few studies have also shown that under certain conditions VEGF can be deleterious. 
 
In vitro findings showed that in explant cultures of dorsal root ganglia, VEGF promotes 
axonal outgrowth and the survival of neurons and Schwann cells. The same effects were 
observed in satellite cells (Sondell et al., 1999). It has been demonstrated that neurons 
express VEGFR-2 and for most of them NRP-1 and that the neurotrophic effects of VEGF 
were mediated by VEGFR-2 signalling (Sondell et al., 2000). At higher doses, a mitogenic 
effect of VEGF on astrocytes was also observed (Silverman et al., 1999). In several 
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pathological conditions, VEGF can be neuroprotective, and studies performed in vitro 
showed that VEGF protected neurons against ischaemia as well as glutamate-induced 
excitotoxicity (Jin et al., 2000a; Matsuzaki et al., 2001). 
 
In vivo, knock-in mice with spinal VEGF levels reduced by 75% developed symptoms related 
to motor neuron degeneration at 5 months of age, resulting in loss of motor coordination, 
muscle atrophy and axonal loss (Oosthuyse et al., 2001), a phenotype very similar to 
amyotrophic lateral sclerosis (ALS). In AD, VEGF immunoreactivity has been demonstrated 
in clusters of reactive astrocytes and diffuse perivascular deposits in patients (Kalaria et al., 
1998) and it is thought to be part of a repair mechanism against hypoperfusion.  
 
VEGF may however have negative effects on the CNS. Recombinant human VEGF (rhVEGF) 
injected intravenously less than an hour after focal embolic ischemia can induce disruption 
of the blood-brain barrier and haemorrhage in ischemic lesions as assessed by MRI 
techniques (Zhang et al., 2000). Moreover, antagonising VEGF reduces oedema formation 
and tissue damage after ischaemia in mice brain (van Bruggen et al., 1999). During 
ischaemic insult, VEGF may also recruit inflammatory cells and promote leukocyte 
adhesion, thus contributing further to neuronal damage. MRI studies in MS lesions have 
shown a positive correlation between VEGF expression in the CNS and the length of lesions, 
suggesting an involvement of VEGF in spinal cord lesions (Su et al., 2006).  Furthermore, as 
discussed before, VEGF may also exacerbate inflammation in MS lesions. An interesting 
study by Zhu and colleagues (Zhu et al., 2008) revealed that delivery of soluble VEGFR-1, 
binding VEGF but lacking the signalling activity, is able to reduce the severity of EAE in rats, 
suggesting that VEGF may play an important role in the pathology of the lesions. Another 
study aimed at reducing spinal cord injury lesions by injecting rhVEGF intraspinally in rats 
 
53 
 
 
 
  
Figure I.4: Summary of the VEGF-VEGFR system, its ligand specificity, cellular 
localization and physiological effects. 
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revealed that animals treated with VEGF actually experienced an exacerbation of the lesion 
volume (Benton and Whittemore, 2003). It was suggested that this exacerbation was due 
to the action of VEGF on vessel permeability.  
 
Finally, VEGF may also play a role in synaptic plasticity. VEGF treatment of hippocampal 
slice before stimulation of neurons at high-frequency increased the long term potentiation 
(LTP) effect while antagonizing VEGFR-2 reduces it (Ruiz de Almodovar et al., 2009). This 
observation combined with the fact that upon NMDA receptor activation, hippocampal 
neurons release VEGF, suggests that VEGF may be involved in synaptic plasticity.  
 
I.5.4 – Existing models of intraspinal injection of VEGF in rats 
 
To our knowledge, two studies have explored the consequences of injecting VEGF into the 
spinal cord in rats where no previous injury or pathology can be found. Benton and 
colleagues (Benton and Whittemore, 2003) studied the effect of recombinant human VEGF 
in rat spinal cord. This was a side experiment completing their study on the effect of VEGF 
injection following spinal cord injury. Briefly, they injected 2µg of recombinant human 
VEGF at the T9 level in the intermediate grey matter at two different sites located 2 mm 
apart and looked at the induced blood brain barrier leakage 30 min, 24h and 72h following 
injection. To do so, they injected HRP intravenously 30min before perfusing the animals 
and removing the cord for immunohistochemical processing. The outcome of this study 
was that HRP extravasation was apparent at 30min and 24h following injection but not at 
72h, indicative of a blood brain barrier leakage resolving before 72h. It is worth noting that 
the extravasation of neutrophils was correlated with the blood brain barrier leakage 
observed. Unfortunately, they did not assess any associated behavioural deficit. 
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On the other hand, Sasaki and colleagues (Sasaki et al., 2010) performed an acute injection 
of VEGF in rats previously injected with incomplete Freund’s adjuvant (i.e. unable to induce 
EAE on its own) as part of a control experiment aimed at inducing focal EAE. 21 days 
following injection of incomplete Freund’s adjuvant, they injected 1 µL of 0.5 mg/mL of rat 
recombinant VEGF at the T9 level, at two different depths (0.7 and 0.5 mm) and at two 
longitudinal sites 2mm apart (thus reaching a total amount of VEGF of 2 x 2 x 0.5µg  =  2µg). 
They then assessed the blood brain barrier leakage by injecting Evans blue immediately 
after VEGF injection. Animals were perfused at 36h and their cord removed for analysis. 
Evans blue leakage was present in the VEGF injected animals but not in the non-injected 
ones, indicative of a blood brain barrier breakdown occurring within 36h (the exact timing 
is impossible to determine because of the protocol used). As animals were scored with the 
EAE score system for detection of EAE symptoms, the group injected with VEGF and 
incomplete Freund’s adjuvant displayed some deficit in the first 3 days following injection 
of VEGF that disappeared further on. This observation was discarded as a surgical trauma. 
However, we believe that because of its correlation with the Evans blue leakage and the 
absence of deficit in another group intraspinally injected with saline, further investigation is 
needed to explain this neurological deficit. 
 
 
I.6- Spinal cord anatomy 
The spinal cord is the means of communication between the brain and the peripheral 
nervous system (PNS). It is constituted of white matter, made of myelinated axons, and 
grey matter, the location of most neuronal cell bodies. Both ascending and descending 
projections connect the brain to the different spinal cord levels to control motor, sensory 
and proprioceptive functions.  
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I.6.1 – Link between the spinal cord and the periphery 
 
Magendie, in 1822, showed that the dorsal roots contain afferent sensory fibres whereas 
the ventral roots contain somatic efferent fibres and presynaptic autonomic fibres. 
The majority of fibres composing ventral roots are somatic motor fibres leaving the ventral 
column of the spinal cord. These are thick myelinated alpha motor axons with high 
conduction velocity controlling muscle contraction and gamma motor axons mainly 
controlling muscle spindle fibres.  
The dorsal roots contain sensory fibres. According to their type and source, the termination 
of these fibres within the spinal cord differs. Thin unmyelinated fibres responsible for 
nociception, temperature and touch are located in the lateral part of the dorsal roots and 
terminate in the superficial laminae of the dorsal horn. On the other hand, thick myelinated 
fibres, such as the Ia afferent fibres, carry sensory information from the muscles and are 
located in the medial part of the dorsal roots, projecting deep into the dorsal and ventral 
horns. Terminations of primary afferents on dorsal horn neurons are arranged in a 
somatotopic manner. For example, distal parts of the limbs connect in the medial part of 
the dorsal horn while proximal parts are located laterally in the dorsal horn (Molander and 
Grant, 1987; Shortland and Woolf, 1993).  
Dorsal and ventral roots join together to form a spinal nerve which is therefore made of 
somatic and visceral fibres that can be either afferent or efferent. Afferent fibres are made 
of axons of dorsal ganglia neurons transmitting external or visceral sensations to the spinal 
cord while efferent fibres are axons of motor neurons or autonomic fibres leaving the 
spinal cord.  
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I.6.2 - Ascending spinal projections 
Ascending spinal projections transmit sensory information such as pain, temperature, 
position and touch from somatic input and pressure, pain from internal organs. The fibres 
composing this pathway are myelinated dorsal root fibres from the dorsal root ganglia and 
axons. Three areas within the spinal cord contain these projections: the ventrolateral 
funiculus, the spinocerebellar tracts and the dorsal column (Kayalioglu, 2009).  
 
The ventrolateral funiculus conveys nociceptive, thermal, touch and pressure information 
to supraspinal levels. One of its major projections is the spinothalamic tract, which 
connects to several thalamic nuclei. The ventral spinothalamic tract conveys crude touch 
and pressure sensations while the lateral part transmits pain and temperature. The 
dorsolateral spinothalamic tract, present in the dorsolateral funiculus, is nociceptive-
specific (Martin et al., 1990). Within the tract, axons are arranged somatotopically; fibres 
from caudal segments are in the medial parts of the tract while more rostral fibres are in 
the lateral parts. In rats, most of the fibres are positioned contralaterally (Burstein et al., 
1990).  
Other ventrolateral projections are the spinoreticular tract which are mostly activated by 
high threshold noxious stimulation but also by low threshold cutaneous stimulation (Sahara 
et al., 1990). More nociceptive tracts connecting to other parts of the brain are present in 
the ventrolateral funiculus: these are the spinomesencephalic and the spinohypothalamic 
tracts.  
 
The spinocerebellar tract carries proprioceptive and cutaneous information to the 
cerebellum, and it is involved in the coordination of movements. The dorsal spinocerebellar 
tract projects mainly ipsilaterally and the fibres are excited by Goups Ia and Ib afferents 
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from muscle spindles and tendon organs respectively (Aoyama et al., 1988) but also by 
Group II fibres for cutaneous touch and pressure. It signals for proprioceptive information 
and allows for coordination of hindlimbs. 
The fibres within ventral the spinocerebellar tract are also activated by Group Ia and Ib 
afferents and transmit information about the entire position and coordination of the limbs.  
 
Axons coming from the dorsal root ganglia enter the dorsal column and form the dorsal 
column pathway by dividing into ascending and descending projections. Long ascending 
projections form the direct dorsal column pathway responsible for discriminatory touch, 
proprioception, deep pressure and vibration input. These projections ascend ipsilaterally 
and are highly organized; fibres from a given segment are lateral to fibres from lower 
segments and are responsible for innocuous mechanical sensations as well as noxious 
stimuli. Short fibres also synapse in the dorsal nucleus of the grey matter whose neurons 
give rise to the spinocerebellar tract. The other neurons coming from dorsal root ganglia 
synapse onto the dorsal horn neurons whose axons ascend in the dorsal column and form 
the postsynaptic dorsal column pathway which controls responses to innocuous stimuli, 
noxious peripheral stimuli as well as visceral nociception. A dorsal intersegmental pathway 
is also present to allow communication between different segments of the cord.  
 
I.6.3- Descending spinal projections and motor neurons 
All mammals possess a very important descending pathway, namely the corticospinal tract 
(figure I.5), which controls motor and sensory functions. These fibres come mainly from 
motor, premotor and somatosensory cortical areas. In rats, this tract is located in the dorsal 
column and its axons connect to the medial parts of the dorsal horns, the intermediate grey 
matter and also motor neurons in the ventral horn. Other tracts, located in the lateral and 
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ventral white matter of the spinal cord also control sensory and motor functions by linking 
brain inputs to the grey matter areas responsible for motor functions (Watson, 2009). 
Among these, the rubrospinal tract (figure I.5) connects to the intermediate grey matter 
and the ventral horn in rats to control motor function and skilled motor tasks (Kuchler et 
al., 2002). The reticulospinal tract (figure I.5), which can be differentiated into the medial 
and lateral reticulospinal tract, are projections responsible for preparatory and movement 
activities and terminate in ventral laminae of the grey matter. The vestibulospinal tracts, 
also split into the lateral and medial tracts (figure I.5), control coordination and posture in 
the limbs and trunk. The lateral one controls extensor tone during locomotion  
(Pompeiano, 1972) while the medial one coordinates the head position with that of the 
body (Wilson et al., 1967). Finally, minor descending tracts also include the tectospinal 
tract, the cerebellospinal tract, the raphespinal and coeruleospinal tracts.  
 
The somatic motor neurons, responsible for skeletal and voluntary muscle control, and 
visceral motor neurons (autonomic system) are located in the grey matter of the spinal 
cord (McHanwell, 2009). Somatic motor neurons are present in the ventral horn and their 
axons innervate fibres leaving the cord via the ventral roots. The axons controlling the hind 
limbs leave the spinal cord and form the sciatic nerve, which innervates the appropriate 
muscles. The sciatic nerve is formed from three spinal nerves that leave the spinal cord at 
the L4, L5 and L6 levels. Importantly, these spinal cord levels are all within the limits of the 
L1 vertebra (Gelderd and Chopin, 1977). 
 
I.6.4- Proprioception  
Propriospinal neurons are neurons that are intrinsic to the spinal cord; their axons 
terminate within its boundaries. They account for most of both the white matter and the 
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grey matter. They modulate afferent and descending input to control locomotion, 
autonomic signals and sensory functions. Within the lumbosacral enlargement (between 
T12-L1 vertebrae in rats), they control the hind limb motor neuron pool by integrating 
peripheral stimuli with muscle contraction and are also involved in hind limb-fore limb 
coordination (Conta, 2009).  
Short propriospinal projections are located in the grey matter (excluding lamina 9) and they 
projects inter-segmentally towards interneurons or lamina 9 motor neurons. Lumbar short 
propriospinal projections are differentially located according to the motor neurons they 
project to (i.e. thigh musculature or distal hindlimb muscles) and these subsets of fibres 
control locomotion. For instance, involuntary stepping can be elicited by stimulation of the 
lumbar spinal cord in individuals with complete cord transection, suggesting that these 
short fibres are able to control lower limb movement (Minassian et al., 2004). 
The long descending propriospinal tracts are located in the deep dorsal horn, the 
intermediate grey matter and dorsal to the central canal and make links between the 
cervical and the lumbar enlargements, thus playing a key role in reflexes and coordination, 
especially during quadrupedal locomotion in rats (Stelzner and Cullen, 1991).  
The long ascending propriospinal tract is the counterpart of the long descending one, 
playing a role in lumbocervical coupling and right-left forelimb alternation (Juvin et al., 
2005).     
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Figure I.5: A. Localization of the main ascending tracts in the spinal cord. B. Localization 
of the main descending tracts in the spinal cord. 
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I.7- Neuronal excitability 
I.7.1- Astrocytes 
There is a bi-directional communication between astrocytes and synapses, which are 
ensheathed in astrocytic endfeet. Astrocytes can release glutamate upon activation and are 
thought to regulate pre-synaptic and postsynaptic activity. This glutamate release is 
thought to be Ca2+-dependent (Bezzi et al., 1998; Pasti et al., 2001) which has been shown 
to induce post-and pre-synaptic depression evoked by electrical stimulation (Araque et al., 
1998). It has also been shown that potentiation of synaptic transmission between 
inhibitory interneurons and pyramidal cells by repetitive firing of interneurons is mediated  
by glutamate release from the neighbouring astrocytes (Kang et al., 1998). Astrocytes also 
use indirect mechanisms to regulate synaptic transmission. Uptake of extracellular 
glutamate is important for termination of synaptic transmission and is primarily performed 
by astrocytes (Rothstein et al., 1996). Release of chemical cofactors can also potentiate 
synaptic transmission. D-serine, released by astrocytes, is an agonist of the glycine-binding 
site of NMDA receptors and allows its activation (Schell et al., 1995). Finally, regulation of 
the concentration of extracellular ions such as K+ and H+ affects neuronal activity, and is 
performed by astrocytes (Newman, 1996; Rausche et al., 1990), providing another means 
by which astrocytes can control neuronal activity. 
 
I.7.2- Inflammation and neuronal excitability 
Inflammation can affect neuronal excitability. It has been shown that activated microglia 
are correlated with the presence of alterations of glutamate re-uptake mechanisms . In MS 
cortical lesions, loss of excitatory amino acid transporters (EAAT), which are responsible for 
controlling the extracellular glutamate concentration, is associated with the activation of 
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microglia (Vercellino et al., 2007). Pro-inflammatory factors such as interleukin-2 (IL-2), 
TNF-α, IFN-γ and nitric oxide (NO) (D'Arcangelo et al., 1991; Fossier et al., 1999; Park et al., 
1995; Tancredi et al., 1992) have been shown to alter synaptic transmission in the CNS. 
Moreover, pro-inflammatory cytokines produced by microglia, such as IL-1β and TNF-α, 
reduced astrocyte-mediated glutamate uptake in an in vitro study (Ye and Sontheimer, 
1996). Pro-inflammatory molecules derived from microglia can also increase neuronal 
stimulation and decrease seizure threshold in epilepsy (Devinsky et al., 2013). The intensity 
of production of these mediators correlates with seizure frequency in epilepsy models 
(Ravizza et al., 2008). Also, activated microglial cells themselves are a source of glutamate, 
hence further contributing to an increase in excitability (Patrizio and Levi, 1994; Piani et al., 
1991).  
 
I.7.3- Blood-brain barrier and neuronal excitability 
Plasma proteins also play a role in excitability alteration in pathological conditions. Entry of 
albumin into the CNS has been shown to induce over-excitability and leads to 
epileptogenesis (Frigerio et al., 2012; Heinemann et al., 2012) by modulating astrocyte-
mediated K+ and glutamate homeostasis (Seifert et al., 2006). The latter study has revealed 
that a focal long-lasting disruption of the blood-brain barrier in the brain leads to activation 
of astrocytes and induction of neuronal over-excitability.  
 
A role for IgG in neuronal dysfunction induced by epileptic episodes has been suggested 
based on a correlation study between IgG leakage into the CNS and epileptic activity in 
patients (Michalak et al., 2012). 
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Thrombin has also been shown to increase NMDA mediated excitability by binding to 
neurons via the PAR-1 receptor (Gingrich et al., 2000) and it increases the neuronal 
response to stimulation (Maggio et al., 2008). 
 
I.7.4- F-wave and H-reflex changes in MS 
Spasticity is a very common symptom of MS, reported in 84% of patients (Rizzo et al., 
2004). Spasticity is thought to be due to a hyper-excitable state of the stretch reflex arc 
(Heckmann et al., 2005). H-reflex amplitude (Voerman et al., 2005) and F wave amplitude 
(Argyriou et al., 2006; Lin and Floeter, 2004) are quantitative methods available to assess 
over excitability of neurons and thus, spasticity. These methods have already been used in 
MS patients to detect spasticity (Argyriou et al., 2010; Bischoff et al., 1992; Smith et al., 
1989; Voerman et al., 2005). 
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I.8- Aim of the study 
Our hypothesis is that breakdown of the blood-brain barrier can lead to alterations of CNS 
function, and cause loss of function. 
Our aims are  
1) to study the direct effects of BBB disruption and plasma leakage in the CNS  
2) to determine the behavioural and motor consequences of BBB disruption 
3) to explore any structural and metabolic changes following BBB breakdown 
 
 
 
 
 
 
 
 
 
 
 
66 
 
Chapter II: Materials and Methods 
II.1- Animal procedures 
A summary of the animal procedures undergone by each goup of animals is provided at the 
end of this chapter in figures II.8, II.9, II.10 and II.11. 
II.1.1- VEGF intraspinal injection 
Adult (250-350g) Sprague Dawley (SD) rats were anaesthetised with 2% isoflurane (Merail, 
Harlow, UK) in room air and the site of operation was shaved and sterilized with iodine. 
Subsequently, animals received a quarter laminectomy of the 13th thoracic (T13-L1) 
vertebra. The T13 vertebra was found by feeling vertebrae through the skin of the animals 
and counting them starting from the L6 vertebra located at the level of the hips. Once the 
spinal cord was exposed, a small incision was made in the dura, and injections of 1µl of 
VEGF164 (Rat VEGF164, R&D Systems, Minneapolis, MN) at a concentration of 1µg/µl in 
sterile PBS were performed at each depth of 0.7mm and 0.4mm in the left dorsal column. 
Injections were made using a drawn glass micropipette held in a micromanipulator, with a 
trajectory of 24 degrees to the vertical. Injection sites were marked with a small amount of 
sterile charcoal. Control animals were injected with sterile phosphate buffered saline (PBS). 
The number of animals per group will be indicated for each experiment reported in the 
results sections. Injections into the animals were made blind to the content of the needle; 
the needle used for each injection was filled with PBS or VEGF by a third person and the 
animal number and the corresponding treatment recorded by this third person. The 
blinding code was kept secret until the very end of the protocol, i.e. any subsequent  
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Figure II.1: Schematic representation of the surgery protocol. Injection sites are 
represented with red crosses.  
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procedure and analysis was performed without knowing whether the animal had been 
injected with VEGF or PBS. 
II.1.2- Evans blue injection 
Two days following surgery and injection of either PBS (n=3) or VEGF (n=5), animals were 
anaesthetised with 2% isoflurane (Merail, Harlow, UK) in room air and, 4% Evans blue 
(Sigma-Aldrich, St Louis, MO) in sterile saline was injected into the right femoral vein 
(1ml/kg) 30min before perfusion. The spinal cords were removed and pictures of the 
injection site were taken using a bright field microscope (Axiophot microscope, Zeiss, 
Oberkochen, Germany). 
 
II.1.3- Pimonidazole injection    
Two days after injection of PBS (n=3) or VEGF (n=5), animals were anaesthetised with 2% 
isoflurane (Merail, Harlow, UK) in room air and, 60mg/ml pimonidazole hydrochloride (HPI, 
Burlington, MA) in sterile saline was injected in the right femoral vein (1ml/kg) 4h before 
perfusion. Spinal cords were removed and prepared as described for immunohistochemical 
labelling for bound pimonidazole. 
 
II.1.4- Perfusion 
Animals were anaesthetised with 3% isoflurane (Merail, Harlow, UK) in room air 
throughout the procedure. An incision was made to expose the peritoneal cavity and the 
chest was opened to expose the heart. The right atrium was severed and a needle inserted 
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into the left ventricle of the heart. A rinse solution (2000U/L heparin, 2% lidocaine, 1% 
NaNO2 and 2M N-2-hydroxyethylpiperazine-NO-2-ethanesulphonic acid (HEPES; pH 7.4) in 
0.9% saline) was perfused through the vasculature until the solution emerging from the 
atrium was clear. Paraformaldehyde (4% in 0.4M phosphate buffer) was then injected. The 
spinal cord was dissected free and placed in paraformaldehyde overnight for further 
processing. 
 
II.1.5- Deficit reversal experiments 
II.1.5.1- Cavtratin injection 
Animals were anaesthetised with 2% isoflurane (Merail, Harlow, UK) in room air and 2.5 
mg/kg of Cavtratin (n=4) (Caveolin-1 scaffolding domain peptide, cell permeable, 
Calbiochem) or the respective scrambled peptide (n=5) in PBS was injected 
intraperitoneally 30 min before injection of VEGF and 24h hour later (before the one day 
time point testing session). Cavtratin is a specific eNOS inhibitor able to block VEGF-
induced blood-brain barrier leakage (Argaw et al., 2012). Animals were tested on the 
horizontal ladder walking test for two days following surgery. At day two, rats were 
perfused and their spinal cord removed to investigate immunohistochemically a potential 
IgG leakage. 
 
II.1.5.2- Oxygen treatment 
Two days following intraspinal injection of VEGF, animals were blindly and randomly 
divided in two groups assigned to receive either room air (n=5) or normobaric hyperoxia 
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(~90% Oxygen, n=5). Animals were first tested on the horizontal ladder test and then 
housed for one hour in a chamber (BioSpherix, USA) where temperature, oxygen 
concentration and carbon dioxide concentration were controlled according to the group to 
which they were allocated. Subsequent to their respective treatments, animals were tested 
again on the horizontal ladder test to assess the effect of treatment on their hind-limb 
scores. After the final test, animals were perfused as described in II.1.4. 
 
II.1.6- Electromyographic (EMG) techniques 
Animals were anaesthetised with xylazine (Xylacare, AnimalCare Ltd)/ketamine (Ketaset, 
Fort Dodge Animal Health Ltd) by i.p. injection. The sciatic nerve was electrically stimulated 
at the sciatic notch and the EMG was recorded at the food dorsum with needle electrodes 
(figure II.2 Top). For each measurement, ten recordings were taken at 10 seconds intervals 
with an oscilloscope (Sigma 60, Nicolet Technologies) and the data transferred to Microsoft 
Excel. Out of these ten recordings, the maximum value of the H reflex amplitude, F and M 
responses amplitudes were used for analysis and comparison (figure II.2 Bottom). At the 
end of the protocol, animals were perfused as described in II.1.4. 
The EMG curve representing the H reflex was differentiated from that representing the F-
wave signals by the absence of M response preceding the H-reflex and the lower stimulus 
strength used to elicit the signals.  
Many parameters (time, temperature, electrode placement) can lead to variability in the 
measurement of H reflex or F response within an animal. As a consequence, the data 
presented here are normalised with the maximal M response, much more stable and 
reproducible. 
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Figure II.2: Top. Summary of the electrophysiology setup: stimulation at the sciatic 
notch, recording at the foot muscle and grounding at the base of the tail. Bottom. 
Summary of the different responses elicited by electrical stimulation at the sciatic 
notch and recorded at the foot muscle (Palmieri et al., 2004). 
 
 
 
 
 
 
Grounding Stimulation 
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II.2- Behavioural analysis 
II.2.1- Ladder test 
Functional deficit was assessed using the ladder test described by Metz and Whishaw (Metz 
and Whishaw, 2002b, 2009). Briefly, animals walked spontaneously on a horizontal ladder 
constructed from irregularly spaced rungs (figure II.3) and a video record was prepared. A 
frame by frame analysis of each step was performed to enable quantification of hind- and 
fore-limb placement and coordination according to a scaling method described in table II.1. 
Each rat performed the test five times in a row at the specified time points. Animals had 
previously been trained for four days before surgery. The last test completed before 
surgery was used as the baseline for subsequent studies. Foot fault scoring and foot 
placement accuracy analysis were performed for each limb for each animal using the video 
recordings. The average of the five trials was then used as the individual measurement for 
each rat. This test allowed gathering data for each paw separately. The averages of both 
fore-limbs and both hind-limbs were calculated and used as the main parameters studied 
to assess the deficit. To assess the potential side-specificity of the deficit, both hind-limbs 
were analysed separately and compared. 
 
II.2.2- Tail angle analysis 
The tail angle is defined as the angle made between a virtual horizontal line and the line 
joining the base of the tail to the tip of the tail (figure II.4)). The horizontal ladder test 
videos were used to measure the tail angle. During each of the 5 trials, when the animals 
was performing 5 consecutive steps on the ladder, a snapshot of the video was taken and 
used to measure the tail angle using the ImageJ software. An average of the 5 trials was 
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then calculated to obtain a single angle per animal. This analysis was performed up to two 
days following injection of VEGF (n=11) or PBS (n=6). 
 
II.2.2- Inclined plane 
During the inclined plane test, each animal was placed facing the upper edge in the middle 
of a wooden rectangular board mounted with a coarse surface and inclined at a specific 
angle (starting at 40°) (figure II.5). Success to stay on the board was defined as the ability to 
stay for 5 seconds at a given angle, repeated for 3 out of 5 consecutive trials. If successful, 
the angle was increased by a 1° increment and the procedure repeated until reaching the 
angle of first fall (3 falls out of 5 trials). The latter was then recorded for each animal and a 
comparison was made between animals injected with VEGF (n=6) and PBS (n=5). 
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Score 
Type of foot 
misplacement 
Characteristics 
0 Total miss Deep fall after limb missed the rung 
1 Deep slip Deep fall after limb slipped off the rung 
2 Slight slip Slight fall after limb slipped off the rung 
3 Replacement Limb replaced from one rung to another 
4 Correction 
Limb aimed for one rung but was placed on another or 
limb position on same rung was corrected 
5 Partial placement 
Limb placed on rung with either digits/toes or 
wrist/heel 
6 Correct placement Mid-portion of limb placed on rung 
 
 
Figure II.3: Snapshot of an animal walking on the horizontal ladder test taken from a 
video recording 
 
Table II.1: Ladder test scoring system (Metz and Whishaw, 2002a) 
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Figure II.4: Schematic representation of the tail angle measured in this study 
 
 
Figure II.5: Inclined plane apparatus 
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II.2.3- Treadmill test – Gait analysis 
Treadmill gait assessment was performed using the TreadScan imaging system. The 
treadmill consisted of a Plexiglas® compartment and a transparent belt with an angled 
mirror placed below, allowing the recording of videos to visualize paw contact during the 
testing procedure. Animals were trained once daily for 4 days before the beginning of 
testing. After being injected with either VEGF (n=5) or PBS (n=5), the testing procedure 
consisted of a 1 min session of walking at a speed of 10 cm/s. This speed was chosen in 
order to allow sick animals to be able to walk at their peak of deficit. The last training 
session was recorded and served as the baseline for normal locomotion. The testing 
protocol consisted of a 1 min walking session once daily according to the time points to be 
studied. Videos were taken and analysed using the TreadScan proprietary software 
(CleverSys), which identifies each individual paw in each frame, outlines them and 
calculates different parameters such as stance time, stride frequency, animal speed, gait 
angle, rear track width, minimal longitudinal reach and feet base. Training session videos 
were used to train the software to correctly use colour and pixel differentiation to identify 
paw placement.  
 
II.2.4- Burrowing test 
Burrowing is a spontaneous natural behaviour in rodents and, as such, an easy test to 
assess the general well-being of these animals (Deacon, 2009). Burrowing behaviour was 
thus analysed as an indicator of the effect of VEGF intraspinal injections in injected rats 
(n=5) compared to the control group (n=4). Burrows were constructed from cardboard 
cylinders of dimensions 300mm long and 90mm in diameter, and they were filled with 
woodchips (figure II.6). The open end of the tube was raised 60mm above the cage floor by 
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two bolts and burrows were filled with woodchip bedding before each test. The test was 
performed every other day from one week pre-surgery up to one month post-surgery. 
Briefly, each animal was housed singly from 6pm until 9am with a burrow filled with 
woodchip bedding. The amount of woodchip bedding burrowed out of the cylinder was 
calculated by comparing the weight of woodchip bedding in the cylinder before and after 
the experiment. Results were expressed as a percentage of woodchip ejected over the 15h 
period. 
 
II.2.5- Von Frey 
To evaluate the consequence of VEGF injection on animals’ response to tactile stimuli, the 
Von Frey filament test was performed. These filaments (Touch Test, Semmes Weinstein) 
are calibrated fibres with ascending force (10g, 15g, 26g, 80g, 100g, 180g, 300g) and the 
accuracy of the calibration was checked by applying the filaments on a scale. Rats were 
placed in a red  Plexiglas® box on a mesh and filaments were applied sequentially to the 
plantar surface of both hind paws, one after the other, until either bending of the filament 
or a withdrawal of the paw was observed (figure II.7). Each filament was tested five times 
on each paw and a given force was considered as the withdrawing threshold when three 
out of five trials resulted in paw withdrawal. This threshold was recorded for each paw of 
each animal at  
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Figure II.6: Burrowing apparatus  
 
 
Figure II.7: Von Frey hair testing apparatus 
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each time point and the animals injected with PBS (n=12) were compared to the ones 
injected with VEGF (n=17). 
 
II.2.6- Statistical analysis 
In each group (control and VEGF-injected animals) ladder test scores, treadmill 
measurement, burrowing scores and inclined plane angles were analysed with a repeated 
measures ANOVA test when all data was normally distributed. If the normality assumption 
was not verified, the non-parametric Friedman test was used. Post-hoc analysis was 
performed with the Student’s t-test between different time points when the data were 
normally distributed. If not the case, the Wilcoxon test was used. Results were accepted as 
significant at p < 0.05. 
Since the Von Frey test score is an ordinary measure of strength leading to paw withdrawal, 
following the non-parametric Friedman test, the non-parametric Wilcoxon test was used to 
compare results between each time point for each paw and each group of animals.  Results 
were considered significant at p < 0.05. 
 
II.3- Immunohistochemistry 
Spinal cords for immunohistochemistry were left in 4% paraformaldehyde (PFA) overnight 
and then put into 30% Sucrose (Sigma-Aldrich, St Louis, MO) and 0.3% sodium azide 
(Sigma-Aldrich, St Louis, MO) in PBS for 48h minimum. Tissue of interest was cut into 5mm 
blocks and frozen on dry ice in optimal cutting temperature (OCT) solution (Bright, 
Huntingdon, UK) and stored at -80°C. 12µm thick transverse sections were cut at -20°C on a 
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cryostat (CM 1950, Leica, Milton Keynes, UK) and mounted on slides (2 sections/slide). 
Slides were left to dry overnight and then stored at -20°C. 
 
II.3.1- Localization of the centre of the lesion 
Within the 5mm block described above, care was taken to accurately find the centre of the 
lesion as the block was taken from the spinal cord by hand, giving the opportunity to 
introduce a slight error of localization during the cutting. The centre of the lesion was then 
accurately found by labelling several slides covering the whole block at 400 µm intervals for 
IgG, which was the best marker for blood-brain barrier leakage and, as a consequence, for 
the presence of the lesion. The section with the most intense IgG labelling was recorded 
and subsequent immunohistochemical labelling performed on adjacent sections. For each 
labelling, one section per animal was used and analysed. Thus, for a given study, the n 
number of sections analysed for quantification is equal to the n number of animals used. 
 
II.3.2- Tissue preparation 
Before immunohistochemical processing, slides were dried at room temperature for a 
minimum of one hour. The area around sections was delimited with a block pen and slides 
were washed with PBS containing 0.3% Triton-X (PBST) for 3x5 min. Depending on the 
antibody used, different pre-treatments were used for antigen retrieval and inhibition of 
endogenous peroxidase activity. 
 Tissue meant to be labelled with 3-3’ diaminobenzidine (DAB) was pre-treated with 
70% methanol and 10% hydrogen peroxide in water to suppress any endogenous 
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peroxidase activity (on which the labelling mechanism is based) for 15min at room 
temperature. 
 Tissue meant to be fluorescently labelled was pre-treated with 70% methanol in 
water for permeabilisation of the tissue. 
 For nitrotyrosine labelling, slides were immersed in 10 % target retrieval solution 
(DAKO) in water at 40°C for 40min. 
 For pimonidazole and HIF labelling, slides were immersed in 0.1% sodium 
borohydride in water for 2x5min to unmask antigens. 
Pre-treatment relative to each antibody is summarized in table II.1. 
 
II.3.3- Primary labelling 
Tissue was blocked with 10% of the appropriate serum (see table II.2) in PBST for 30 min 
before incubation overnight at 4°C in 200µl of primary antibody diluted at the optimal 
concentration (table II.2) in 2% blocking serum in PBST.  
II.3.4- Secondary labelling and amplification 
 DAB labelling 
Biotin-coupled secondary antibodies (listed in table II.2) were applied for 1h at room 
temperature. Amplification was achieved with the Vectastain ABC Elite kit (30min room 
temperature, Vector Labs, Peterborough, UK) and a triple 5min PBST wash was performed 
between each step. Labelling with DAB (Vector labs, Peterborough, UK) was timed as 
appropriate for the relevant antibody (listed in table II.2) and the reaction was stopped 
with water. Slides were then immersed in ethanol and xylene in ascending concentrations: 
82 
 
70% (5min), 90% (5min), 100% (2min), 100% (2 min), xylene (2min), xylene (2min), 
mounted in DPX and stored at room temperature. 
 Fluorescent labelling 
Secondary antibodies, consisting of either fluorescently labelled antibody (Cyanine 3 (Cy3) 
or Fluorescin isothiocyanate (FITC)) or biotin-coupled antibody (listed in table II.2), were 
applied for 1h at room temperature followed by 1h incubation with Streptavidin (SAV) 488 
for biotin-coupled secondary antibodies. After a triple PBST wash, slides were mounted 
with DAPI fluorescent medium and stored at 4°C. 
 
II.3.5- H&E staining 
Slides of transverse sections of the spinal cord were used for haematoxilin and eosin (H&E) 
staining. After drying for 1 hour at room temperature, a triple 5 min PBS watch was 
performed. Slides were then incubated for 2 min in a haematoxylin solution and washed 
again for 15 min under running tap water. They were incubated in eosin for 2 minutes 
before being washed again for 15 min with running tap water. Slides were then immersed 
in ethanol and xylene in ascending concentrations: 70% (5min), 90% (5min), 100% (2min), 
100% (2 min), xylene (2min), xylene (2min), mounted in DPX and stored at room 
temperature. 
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II.3.6- Microscopy analysis 
DAB labelled sections and plastic sections were examined by light microscopy (Axiophot 
microscope, Zeiss, Oberkochen, Germany) and pictures were taken using a Nikon D300 
camera (Nikon, Tokyo, Japan). Fluorescent labelling was observed through an LSM 5 Pascal 
confocal microscope (Zeiss, Oberkochen, Germany) and pictures were recorded and 
analysed with the Pascal software (Zeiss). 
 
II.3.7- ED1, MHC class II and RECA-1 labelling quantification 
Following immunohistochemical labelling of spinal cord sections, low magnification (10x) 
pictures were taken. Using ImageJ software, pictures were thresholded using the “color 
threshold” tool in order to differentiate between background and positive labelling. Once 
the threshold was applied to the image (the value of the threshold was kept constant for all 
images), they were converted into an 8 bit black and white format and transformed into 
binary black and white pictures using the “make binary” tool with the white background 
option selected. Particles to be counted were therefore black, and using the drawing tool, 
the area of interest was delimited and particles labelled in black were counted using the 
“Analyze particles” tool. Results were expressed as a number of positive particles per area. 
 
II.3.8- Statistical analysis 
To show significance of the results, statistical analysis was performed on ED1 and MHC-II 
cell counts between the control group and the VEGF injected animals.  Student’s t-test was 
performed for normally distributed measurements and the Mann Witney U-test was used 
for non-parametric evaluations. Results were considered significant for p < 0.05. 
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II.4- Plastic sections 
Spinal cords for plastic sectioning were put in 4% (PFA) overnight. Tissue of interest was cut 
into 1mm thick blocks and left for at least 24h in 4% glutaraldehyde.  Tissue was then 
subjected to three 10min washes in 0.1 M PO4 buffer (pH 7.4) and post-fixed in 1.5% 
osmium tetroxide for 1h, before undergoing a further set of three 10min washes in 0.1 M 
PO4 buffer (pH 7.4). Spinal cords were then dehydrated in 15min washes in 30%, 50%, 70% 
and 90% ethanol ending with three 20min washes in 100% anhydrous ethanol. For resin 
infiltration, two 30min washes in 100% propylene oxide were followed by 2h in 75% 
propylene oxide: 25% resin, 2h in 50% propylene oxide: 50% resin, 2h in 25% propylene 
oxide: 75% resin and finally overnight at 4ºC in fresh 100% resin. The tissue was embedded 
in resin, using Beem capsules for longitudinal sections or coffin molds for transverse 
sections, and heated at 60°C for 48 hours. 0.7μm thick sections were cut and collected onto 
slides and stained with thionin acetate and acridine orange. These sections were then 
screened in a light microscope and ultrathin sections from selected blocks were 
subsequently examined further in an electron microscope.  
 
II.5- Grey matter area ratio 
The size of the grey matter on the ipsilateral side of the spinal cord was compared to the 
contralateral side by using plastic sections or sections stained with H&E. Briefly, 5x pictures 
were taken with a light microscope (Axiophot microscope, Zeiss, Oberkochen, Germany) 
and, using ImageJ analysis software, the grey matter was delimited using the drawing tool 
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and the area measured. The ratio ipsilateral/contralateral area was then calculated and 
plotted. 
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Primary 
antibody 
Source Dilution Company Pre-treatment 1 Pre-treatment 2 Blocker Secondary Labelling 
IgG + HRP Goat, polyclonal 1/200 Sigma Aldrich Met + Peroxide   Goat  N/A DAB: 4min 
iNOS Rabbit, polyclonal 1/200 BD Transduction 
Lab.  
Met + Peroxide   Goat Goat anti-rabbit biotinylated DAB: 6min 
ED1 Mouse, monoclonal 1/200 AbD Serotec Met + Peroxide   Horse Horse anti-mouse biotinylated DAB: 1min 
Pimonidazole Mouse, monoclonal 1/200 HPI Inc. Met + Peroxide Sodium borohydride Casein Horse anti-mouse biotinylated DAB: 30min 
Nitrotyrosine Mouse, monoclonal 1/200 Millipore Met + Peroxide DAKO retrieval Horse Horse anti-mouse biotinylated DAB: 5min 
Ox-42 Mouse, monoclonal 1/200 Abcam Met + Peroxide   Horse Horse anti-mouse biotinylated DAB: 5min 
HIF Rabbit, polyclonal 1/200 Millipore Met + Peroxide Sodium borohydride Goat Goat anti-rabbit biotinylated DAB: 3.5min 
Fibrinogen Goat, polyclonal 1/500 Nordic 
Immunology 
Met   Rabbit Rabbit anti-goat biotinylated SAV 488 
GFAP Mouse, monoclonal 1/200 Abcam Met   Horse Horse anti-mouse biotinylated SAV 488 
VEGF Mouse, monoclonal 1/200 Abcam Met   Horse Horse anti-mouse biotinylated SAV 488 
MHC class II Mouse, monoclonal 1/200 Abcam Met   Horse Horse anti-mouse biotinylated SAV 488 
CD 3 Rabbit, polyclonal 1/200 Abcam Met   Goat Cy-3 conjugated Goat anti-
rabbit  
  
Synaptophysin Mouse monoclonal 1/100 Abcam Met DAKO retrieval Horse Horse anti-mouse biotynilated SAV 488 
PSD-95 Rabbit polyclonal 1/1000 Abcam Met DAKO retrieval Goat Goat anti-rabbit biotinylated SAV 488 
RECA-1 Mouse, monoclonal 1/500 Abcam Met   Horse Horse anti-mouse biotinylated SAV 488 
Table II.2: Primary antibodies used with their respective blocker, dilution and pre-treatment (Met: Methanol 70%, Peroxide: Hydrogen Peroxide). 
Secondary antibodies are shown with their respective labelling method (time of incubation in DAB is given, SAV 488: Alexa Fluor 488 conjugate). 
 
Figure II.8: Primary antibodies used with their respective blocker, dilution and pre-treatment (Met: Methanol 70%, Peroxide: Hydrogen Peroxide). 
Secondary antibodies are shown with their respective labelling method (time of incubation in DAB is given, SAV 488: Alexa Fluor 488 conjugat 
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Figure II.8: Summary of the procedures undergone by each group of animals used in the 
study (1) 
 
Figure II.8: Primary antibodies used with their respective blocker, dilution and pre-treatment 
(Met: Methanol 70%, Peroxide: Hydrogen Peroxide). Secondary antibodies are shown with 
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Figure II.9: Summary of the procedures undergone by each group of animals used in the 
study (2) 
 
Figure II.8: Primary antibodies used with their respective blocker, dilution and pre-treatment 
(Met: Methanol 70%, Peroxide: Hydrogen Peroxide). Secondary antibodies are shown with 
their respective labelling method (time of incubation in DAB is given, SAV 488: Alexa Fluor 
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Figure II.10: Summary of the procedures undergone by each group of animals used in the 
study (3) 
 
Figure II.8: Primary antibodies used with their respective blocker, dilution and pre-treatment 
(Met: Methanol 70%, Peroxide: Hydrogen Peroxide). Secondary antibodies are shown with 
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Figure II.11: Summary of the procedures undergone by each group of animals used in the 
study (4) 
 
Figure II.8: Primary antibodies used with their respective blocker, dilution and pre-treatment 
(Met: Methanol 70%, Peroxide: Hydrogen Peroxide). Secondary antibodies are shown with 
their respective labelling method (time of incubation in DAB is given, SAV 488: Alexa Fluor 
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Chapter III: Results - Behavioural 
analysis 
 
III.1- Choice of the injection dose 
Preliminary studies were necessary to determinate the dose of VEGF to be injected in the 
spinal cord. One research group, however, has injected directly VEGF intraspinally in rats to 
provoke a focal EAE lesion (Sasaki et al., 2010). Basing our protocol on their study, we 
decided to inject rats with VEGF at the T13-L1 vertebral level (where the hind limbs motor 
neurons pool is located) in the dorsal column at two different doses: 2x1µL at 1 mg/mL 
VEGF (low dose) and 4x1µL of 1 mg/mL (high dose). We then assessed the motor function 
of hind limbs of animals for up to one month post-surgery with the horizontal ladder 
walking test.  
 
Control animals (injected with low (n=4) or high (n=4) dose of PBS) did not demonstrate 
any deficit on the ladder test for the whole course of the study. In contrast, animals 
injected with VEGF at both low dose (n=3) and high dose (n=2) (note: these small group 
sizes were just for determining the dose) showed a transient and reversible deficit starting 
at day two as shown in figure III.1. The low dose group showed a milder and quantifiable 
deficit (figure III.1.A) while the high dose animals were paralysed from the hind limbs at day 
one and two following surgery and recovered from day three onward (figure III.1.B).  
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Figure III.1: A. Relative hind limb score on the horizontal ladder test of animals injected with 
PBS (n=4) or a low dose (2x1µg) of VEGF (n=3). Day 0 corresponds to the date of surgery. B. 
Relative hind limb score on the horizontal ladder test of animals injected with PBS (n=4) or a 
high dose (4x1µg) of VEGF (n=2). Animals were tested from seven days before surgery up to 
27 days post-surgery. Day 0 corresponds to the date of surgery. Error bars represent the 
standard error of the mean. 
A 
B 
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It is worth noting that, as expected, only the hind limbs exhibited a deficit after VEGF 
injection: in another study, the scores for both fore limbs for VEGF-treated animals (n=6) 
were comparable to control animals (n=4) for the whole period of study (figure III.2). 
Interestingly, the deficit in the hind limbs had no effect on the ability of the animals to use 
the fore limbs on the ladder. Because of the ability to quantify the deficit undergone by 
animals injected with a low dose of VEGF, the low dose protocol was preferred. This choice 
was justified by the prospect of assessing quantifiable differences between possible 
mechanisms of actions and causes of deficit. For the rest of the study, the dose injected is a 
dose corresponding to a low dose of VEGF: 2x1µL at 1 mg/mL.  
 
III.2- Motor deficits induced by injection of VEGF 
III.2.1- Horizontal ladder test 
Animals injected with VEGF were compared with controls on the horizontal ladder walking 
test on different days over a month. As expected, control animals did not show any 
deficiency while performing the task but animals injected with VEGF showed a deficit 
during days one and two post-surgery, and recovered from day three until the end of the 
study, as shown by their hind limb score (figure III.1). Noticeably, two animals (not included 
in the data shown in figure III.1), showed a complete hind-limb paralysis (explained by the 
subsequent histological discover that the VEGF injection went into the grey matter leading 
to haemorrhage) and recovered within the same time course as correctly injected animals.  
 
As the deficit was observed within the first three days following surgery, with subsequent 
recovery, the focus of most subsequent studies has been during the first days of lesion  
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Figure III.2: Relative fore-limb score on the horizontal ladder test of animals injected with 
PBS (n=4) or VEGF (n=6). Animals were tested from seven days before surgery up to 27 days 
post-surgery. Day 0 corresponds to the date of surgery. Error bars represent the standard 
error of the mean. 
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development. Moreover, as described in the introduction, the motor neuron pool and 
proprioceptive pathway mediating hind limb control is located in the lumbrosacral 
enlargement, between the T12 and L1 vertebrae. To verify the accuracy of the hind-limb 
control location, rats were injected at either T12-T13 or T13-L1 levels with VEGF or PBS and 
tested for three days before perfusion. Data are shown in figure III.3 and show a significant 
deficit (T12-T13: p=0.003 n=10; T13-L1: p=0.012 n=8) at day two post-surgery in animals 
injected with VEGF in either injection locations. Control animals did not show any score 
reduction in any of the injection locations (T12-T13: n=8; T13-L1: n=8). The amplitude of 
the deficit was similar between animals injected at T12-T13 (23.76 +/- 11.9%, n=8) or T13-
L1 (28.4 +/- 11.08%, n=10). Thus for both injection sites, VEGF injection causes a significant 
neurological deficit at day two post-surgery compared to the baseline and control animals.  
 
The data presented so far are an average of the scores for both hind-limbs. As a 
consequence, no difference between left and right hind-limbs can be observed from these 
data. However, the horizontal ladder walking test allows for discrimination between 
different limbs by analysing them separately (Metz and Whishaw, 2002a, 2009). This limb-
specific analysis has been performed on 19 VEGF-injected animals and 13 control animals. 
Interestingly, whereas VEGF was injected on the left side of the cord, left and right hind-
limbs had a similar deficit amplitude as shown in figure III.4. No side-specific effect was 
observed. 
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A 
Figure III.3: A. Relative hind limb score on the horizontal ladder test of animals injected with 
PBS (n=3) or VEGF (n=8) at the T13-L1 vertebral level. B. Relative hind limb score on the 
horizontal ladder test of animals injected with PBS (n=10) or VEGF (n=11) at the T12-T13 
vertebral level. Animals were tested from one day before surgery up to three days post-
surgery. Day 0 corresponds to the date of surgery. Statistical analysis was performed with a 
Wilcoxon test. (*: p<0.05). Error bars represent the standard error of the mean. 
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Figure III.4: Relative hind limb score on the horizontal ladder test of animals injected with 
PBS (n=13) or VEGF (n19). Left and right hind-limbs scores were assessed separately and are 
represented. Animals were tested from one day before surgery up to three days post-
surgery. Day 0 corresponds to the date of surgery. Statistical analysis was performed with a 
Wilcoxon test. (***: p<0.001). Error bars represent the standard error of the mean. 
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III.2.2- Tail position 
During the ladder test it was noticed that some animals held their tail abnormally. Thus, 
both naïve and saline-injected (n=6) rats walked with the tail lifted high, whereas animals 
injected with VEGF (n=11) either dragged their tail, or only lifted it slightly. Quantification 
of the tail angle (figure III.5) confirmed this impression, revealing that at day two following 
surgery VEGF injected animals carried their tails at a significantly reduced angle compared 
with baseline values (p=0.008). A trend is present at one day. This result reveals that VEGF 
injection impairs both hind limb and tail function. 
 
III.2.3- Inclined plane test 
The inclined plane method was used to explore further the impairment in motor function in 
the rats injected with VEGF. No difference was observed in the plane angle between one 
day before (baseline) and after surgery in both control (54.6° +/- 0.84°, n=5) and VEGF-
treated animals (55.8° +/- 0.2°, n=5), but there was a significant difference (p=0.043) at day 
two. Thus, slipping occurred at a lower angle compared to baseline in treated animals 
(45.2° +/- 0.58°, n=5), but not in controls (53.17° +/- 2.41°, n=5) (figure III.6).  
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Figure III.5: Relative tail angle value while walking on the horizontal ladder of animals 
injected with PBS (n=6) or VEGF (n=11). Animals were tested from one day before 
surgery up to three days post-surgery. Day 0 corresponds to the date of surgery. 
Statistical analysis was performed with a Wilcoxon test. (**: p<0.005). Error bars 
represent the standard error of the mean. 
Figure III.6: Inclined plane test. Maximal angle before slip for animals injected with PBS 
(n=6) or VEGF (n=5). Animals were tested from one day before surgery up to three days 
post-surgery. Day 0 corresponds to the date of surgery. Statistical analysis was 
performed with a Wilcoxon test. (*: p<0.05). Error bars represent the standard error of 
the mean. 
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III.2.4- Treadmill test 
The motor deficit resulting from the injection of VEGF was characterized further using an 
automated treadmill test that assessed a range of measures of locomotor function.   
 General observations 
On the automated treadmill, videos of the animals could be recorded while walking, 
allowing for an observation of their gait. As shown in the snapshots presented in figure III.7, 
a difference could be observed between control animals and animals injected with VEGF. 
While walking, the hind limbs of control animals were kept at a consistent distance from 
each other and their toes were constantly spread. In contrast, animals injected with VEGF 
walked with their hind limbs very close to each other, almost in line along the longitudinal 
axis, and the spreading of the toes was absent. 
 Feet base  
The feet base is the side-specific distance between the midpoint of the front paw stride and 
the midpoint of the rear paw stride. In control animals (n=8), the feet base remained stable 
from baseline prior to surgery up to three days post-surgery (figure III.8.B). At two days 
post-surgery, VEGF-treated animals showed a longer feet base measure compared to 
baseline, one day and three days post-surgery values. This effect was amplified ipsilaterally 
to the injection side and is in line with the deficit characterized so far.  
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 Gait angle 
The gait angle is the angle between the line connecting the plantar position of one rear foot 
to the next plantar position of the same foot and the line connecting the plantar position of 
that same rear foot to the next plantar position of the opposite rear foot. It is a combined 
singular measure of stride width and length. No difference between the control group (n=8) 
and the VEGF treated group (n=5) was observable at baseline, one day or three days post-
surgery (figure III.8.A). However, at day two following intraspinal injections, animals that 
received VEGF showed a decrease in the gait angle compared with animals that received 
PBS. The change did not reach statistical significance, but a clear trend was apparent. As 
the gait angle is a combined measure of stride width and length, it is in agreement with 
both the decrease in track width and the bigger minimal longitudinal reach observed at day 
two post-surgery (figures III.9.A and III.9.B). 
 Rear track width 
The rear track width is the distance between the midpoint of the rear left paw stride and 
the midpoint of the right rear paw stride. As show in figure III.9.A, the rear track width of 
control animals (n=8) was not affected by injection of PBS. On the contrary, the rear track 
width of VEGF injected animals (n=5) showed a non-significant trend towards reduction 
two days post-surgery and went back to a baseline level at day three following the injection 
of VEGF.  
 Minimal longitudinal reach 
The minimal longitudinal reach is the closest distance during the stance that the paw 
attained relative to the waist axis, i.e. it measures how close the paw got to the waist. The 
minimal longitudinal reach did not change baseline after surgery in control animals (n=8), 
but there was a trend towards a higher minimal longitudinal reach in VEGF-injected ones.  
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Figure III.8: Movement parameters of animals tested on an automated treadmill from one 
day before surgery up to three days post-surgery. A. Relative gait angle of animals injected 
with PBS (n=8) or VEGF (n=5). Day 0 corresponds to the date of surgery. B. Relative feet 
base values of animals injected with PBS (n=8) or VEGF (n=5). Day 0 corresponds to the date 
of surgery. Using a Wilcoxon test, no statistical significance was achieved at any time point. 
Error bars represent the standard error of the mean. 
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Figure III.9: Position parameters of animals tested on an automated treadmill from one day 
before surgery up to three days post-surgery. A. Relative rear track width of animals 
injected with PBS (n=8) or VEGF (n=5). Day 0 corresponds to the date of surgery. B. Relative 
minimal longitudinal reach of animals injected with PBS (n=8) or VEGF (n=5). Day 0 
corresponds to the date of surgery. Using a Wilcoxon test, no statistical significance could 
be achieved at any time point. Error bars represent the standard error of the mean. 
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 Overall running speed 
The overall running speed is obtained by dividing the total distance travelled by the centre 
of the animal by the time it took to travel that distance. As shown in figure III.10.C, through 
the three days of testing after injection of PBS (n=8) or VEGF (n=5), no change in overall 
speed was observable for any of the groups.  
 Stance time 
The stance time is the time elapsed while the paw is in contact with the treadmill, in its 
stance phase. At day two following surgery, animals injected with VEGF (n=5) had a lower 
stance time compared with PBS-injected animals (n=8), while no difference was observable 
at any other time point, showing a recovery to baseline level at day three post-surgery. 
Although present on both sides, this trend was not statistically significant. Within a given 
group, no difference was observable between the left and right paw (figure III.10.A). 
 Stride frequency 
The stride frequency is the ratio of the number of strides to the sum of the stride times of 
these strides. This yields the number of strides per second (Hz) for the given paw. An 
increase in stride frequency was present at day two post-surgery for the VEGF treated 
group (n=5) but not in the PBS injected group (n=8) (figure III.10.B). At other time points, no 
difference between the groups could be observed. Similarly to the stance time, no 
difference between left and right paws was present within a given group. This result is in 
line with the decrease in stance time and the absence of change in overall speed, leading to 
a higher stride frequency to keep the same pace. 
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animals (n=5) two days post-surgery (figure III.9.B), temporally correlated with the motor 
deficit in the horizontal ladder test. This increase was strongest on the injected side. 
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Figure III.10: Speed parameters of animals tested on an automated treadmill from one day 
before surgery up to three days post-surgery. A. Relative stance time of animals injected 
with PBS (n=8) or VEGF (n=5). Day 0 corresponds to the date of surgery. B. Relative stride 
frequency of animals injected with PBS (n=8) or VEGF (n=5). Day 0 corresponds to the date 
of surgery. C. Relative speed of animals injected with PBS (n=8) or VEGF (n=5). Day 0 
corresponds to the date of surgery.  Using a Wilcoxon test, no statistical significance was 
achieved at any time point. Error bars represent the standard error of the mean. 
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III.3- Behavioural deficits induced by injection of VEGF 
It is a natural behaviour for rodents to burrow (Deacon, 2006), so burrowing activity can be 
used as a sensitive method to assess general behavioural dysfunction. To make the 
assessment, five rats injected with VEGF, and four controls, were housed singly in cages 
overnight (and put back with their cage mates during the day). The cages contained a 
burrow filled with wood chip bedding, and the burrowing activity was measured by 
weighing the remaining contents. A significant reduction in burrowing behaviour was 
observed with VEGF-treated animals at one (p=0.043), two (p=0.043) and three (p=0.043) 
days post-surgery compared with their pre-surgery baseline (figure III.11). The decreased 
burrowing activity correlated with their decreased motor dysfunction (compare figures III.3 
and III.11). No significant difference was observed between the control- and VEGF-injected 
groups after the first three days following surgery (figure III.11). 
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Figure III.11: Burrowing activity of animals injected with PBS (n=4) or VEGF (n=5).Animals 
were tested from 13 days before surgery up to 18 days post-surgery. Day 0 corresponds to 
the date of surgery. Statistical analysis was performed with a Wilcoxon test. (*: p<0.05). 
Error bars represent the standard error of the mean. 
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III.4- Sensory deficits induced by injection of VEGF 
The sensory pathway from the hind limbs may be affected by the spinal lesion (at the T12-
L1 vertebrae), so it was of interest to determine whether the injection of VEGF changed the 
responsiveness of the hind limbs to touch stimuli. The von Frey hair test was performed on 
the hind paws of 17 animals injected with VEGF and 12 control animals injected with PBS. 
The results displayed in figure III.12 show a decrease in sensitivity from baseline of both the 
left (p=0.002) and right (p=0.003) hind-paws in VEGF-treated animals, whereas no 
significant change was observed in controls. Thus, in animals injected with VEGF, the 
ipsilateral hind paw required a greater stimulus (115 g) to elicit withdrawal than the 
contralateral paw (105 g). This finding indicates that the injection of VEGF desensitizes the 
hind paws to tactile stimuli. 
III.5- Long term effect of injection of VEGF 
To assess whether the intraspinal injection of VEGF can have any long term effect on 
animals, we used the horizontal ladder test and assessed animals injected with PBS or VEGF 
for one year following surgery. As expected, a hind limb deficit was observable at day two 
post-surgery in VEGF-injected animals (n=6) compared to controls (n=3) (p=0.043) (figure 
III.13). During the following year, no difference in behaviour or ladder score could be 
observed, the animals injected with VEGF did not show any sign of deficit, indicating that 
injection of VEGF did not have any long term effect on motor function. 
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Figure III.12: Paw withdrawal threshold in grams of animals injected with PBS (n=12) or 
VEGF (n=17). A. Left hind limb. B. Right hind limb. Animals were tested from one day before 
surgery up to two days post-surgery. Statistical analysis was performed with a Wilcoxon 
test. (**: p< 0.005). Horizontal bars represent the median of each group. Each point 
represents the measurement for one animal.  
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Figure III.13: Relative hind limb score on the horizontal ladder test of animals injected with 
PBS (n=3) or VEGF (n=6) from one day before surgery up to a year following injection. Note 
that the abscissa is non-linear.  Day 0 corresponds to the date of injection. Statistical 
analysis was performed with a Wilcoxon test. (*: p<0.05). Error bars represent the standard 
error of the mean. 
B
as
el
in
e
1 
D
ay
2 
D
ay
s
3 
D
ay
s
1 
W
ee
k
2 
W
ee
ks
1 
M
on
th
2 
M
on
th
s
3 
M
on
th
s
5 
M
on
th
s
1 
Y
ea
r
50
60
70
80
90
100
110
PBS injected
animals (n=3)
VEGF injected
animal (n=6)
*
R
e
la
ti
v
e
 h
in
d
 l
im
b
 s
c
o
re
(%
 o
f 
b
a
s
e
li
n
e
 v
a
lu
e
)
  
112 
 
Chapter IV: Results - 
Immunohistochemical analysis 
 
IV.1- Blood-brain barrier breakdown 
IV.1.1- Evans blue leakage 
Evans blue is a dye commonly used to assess leakage of blood vessels in the CNS (Olsson et 
al., 2006; Sasaki et al., 2010). The dye binds to blood albumin irreversibly (Veikkola et al., 
2001) and gives a blue colour to any tissue into which labelled albumin may have leaked. 
On the second day following VEGF injection, Evans blue was administered intravenously in 
both animal groups (5 rats injected with VEGF and 3 with PBS) 30 minutes before perfusion. 
As shown in figure IV.1.A, all animals treated with VEGF (n=5) showed a focal blue staining 
specifically at the lesion site, indicating the presence of labelled albumin in the spinal cord. 
Control animals (n=3) did not show any sign of leakage (figure IV.1.A). The staining was 
consistently present around the injection site and extended longitudinally over an average 
of 5 to 6 mm, suggesting that a blood-brain barrier breakdown occurs over up to 3 mm 
away from the injection site. The extent of the lesion (measured by Evans blue leakage) 
was long enough to occur at the zone of entry of the sciatic nerve into the spinal cord 
(figure IV.1.B), confirming that the location chosen for VEGF injection is appropriate for 
targeting the motor function of the hind limbs. 
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VEGF Control 
Figure IV.1:  A. Spinal cord of animals injected with VEGF (Left) or PBS (right) and intravenous 
Evans blue 30 min before perfusion at day two following surgery. B. Spinal cord of an animal 
injected with VEGF (the injection site is located by putting sterile charcoal where the needle 
was inserted) removed altogether with the spinal roots projecting to the left sciatic nerve. 
The black bar represents the extent of the lesion observed with Evans blue leakage, and 
covers the zone of entry of the roots from the sciatic nerve into the spinal cord. Scale bar: 
5mm. 
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IV.1.2- IgG leakage 
Blood-brain barrier disruption within the spinal cord was also assessed by IgG 
immunohistochemical labelling in spinal cord sections. Spinal cords of rats injected with 
VEGF or PBS were taken at different time points (one day, two days and three days 
following surgery) and processed to investigate the presence of IgG. Results (figure IV.2) 
show the presence of IgG in VEGF-injected spinal cords, but not in PBS-injected tissue, 
indicative of a breakdown of the blood-brain barrier. Interestingly, the highest amount of 
IgG was found at one and two days post-surgery. IgG was still present at three days post-
injection although in a lesser extent. The IgG peak during the first two days following 
surgery is in agreement with previous studies showing that VEGF induces blood-brain 
barrier breakdown from day one to day three (Benton and Whittemore, 2003). Labelling 
was present throughout the whole spinal cord cross section although a higher labelling for 
IgG was found in the grey matter compared with the white matter.  
IV.1.3- Fibrinogen extravasation 
We investigated whether fibrinogen is present within the rat spinal cord as a consequence 
of VEGF injection. Similarly to IgG, we looked for infiltration of fibrinogen at different time 
points (one, two and three days following surgery) and at different locations within the 
cord, namely the dorsal column, both dorsal horns, both ventral horns and the base of the 
dorsal column. Fibrinogen was present in the spinal cords of animals treated with VEGF but 
absent from control tissue (figure IV.3 and IV.4). All the areas examined showed fibrinogen 
extravasation at all time points, with a tendency to diminish at day three post-surgery. 
Moreover, a tendency for a higher intensity in the ipsilateral side is detectable in VEGF-
injected animals (figures IV.3 and IV.4). 
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Figure IV.2:  IgG labelling in spinal cords of animals treated with VEGF (bottom row) or 
PBS (top row) at one day (left column), two days (middle column) and three days (right 
column) post-surgery. Scale: 600µm. Injections were made on the left side of the dorsal 
column. The black dot shows the side of injection. 
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Figure IV.3:  Fibrinogen labelling in spinal cords of animals treated with VEGF (right 
column) or PBS (left column) at one day (top row), two days (middle row) and three days 
(bottom row) post-surgery. Pictures were taken in the dorsal column (top panel), the left 
base of the dorsal column (bottom left panel) and the right base of the dorsal column 
(bottom right panel). Scale: 20µm. Injections were made on the left side of the dorsal 
column. 
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Figure IV.4:  Fibrinogen labelling in spinal cords of animals treated with VEGF (right 
column) or PBS (left column) at one day (top row), two days (middle row) and three 
days (bottom row) post-surgery. Pictures were taken in the left dorsal horn (top left 
panel), the right dorsal horn (top right panel), the left ventral horn (bottom left panel) 
and the right ventral horn (bottom right panel). Scale: 20µm. Injections were made on 
the left side of the dorsal column. 
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IV.2- Structural changes induced by injection of VEGF 
To assess the effect of VEGF on the spinal cord tissue, plastic sections of VEGF-injected 
spinal cords were analysed. Sections were taken at two days post-surgery (during the peak 
of deficit of VEGF-treated animals) at the injection site of animals treated with VEGF (n=10) 
and compared with control tissue (PBS-injected, n=4). Changes in neuron structure, 
demyelination, degeneration or presence of oedema were investigated in the whole spinal 
cord with a focus on the dorsal column where the injection was made. In both VEGF- and 
PBS-treated groups, no oedema could be observed two days following injection (figure IV.5, 
top and middle row). Also, no degeneration or demyelination was present after injection, 
indicating that VEGF injection (and PBS) has no obvious effect on the structure of the spinal 
cord. The motor nuclei of the ventral horn did not show any structural change following 
injection of VEGF. Motor neurons in tissue injected with VEGF had a similar appearance to 
the motor neurons of PBS-injected tissue (figure IV.5, bottom row). Moreover, the ratio 
between in ipsilateral and contralateral grey matter was measured. Results are presented 
in figure IV.6. For both groups, VEGF-injected (n=10) and control (n=4), the ratio was very 
close to 1, indicating that no difference between the ipsilateral and contralateral side was 
present (figure IV.6). 
 
The same study has been performed one month (VEGF: n=6, PBS: n=4) after surgery to 
assess any long term change due to VEGF. Analysis of plastic sections led to the same 
conclusion as the two days post-surgery tissue, i.e. that no structural changes were 
apparent in any part of the spinal cord. 
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Figure IV.5: Plastic transverse sections of spinal cords of animals injected with VEGF (right 
column) or PBS (left column) at 5x (top row, scale: 600µm). Middle row shows the base of 
the dorsal column (20x, scale: 75µm) and bottom row shows the ipsilateral motor nuclei of 
the ventral horn (100x, scale: 40µm) two days after surgery. Injections were made on the 
left side of the dorsal column. The black dot shows the side of injection. 
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Figure IV.6: Grey matter area ratio measured two days after surgery between the 
ipsilateral side of injection and the contralateral side of injection in PBS- (n=4) and VEGF- 
(n=6) injected animals. Error bars represent the standard error of the mean. 
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IV.3- Angiogenic effects of injection of VEGF 
Since VEGF is a vascular endothelial growth factor involved in angiogenesis, the effect of 
VEGF on blood vessels has been assessed by labelling of blood vessel density with the rat 
endothelial cell antibody (RECA-1). Blood vessels were counted and their shape 
qualitatively examined in the dorsal column and in the grey matter bordering the dorsal 
column. Examination of the blood vessel structure and number showed that a single 
injection of the dose used in this study is not sufficient to induce any change at two days-
post surgery in terms of blood vessel number (figure IV.7.B) or shape (figure IV.7.A). 
 
IV.4- Inflammatory response following injection of VEGF 
Since the deficit observed in behavioural tests could not be explained by any structural 
change within the spinal cord following VEGF injection, a metabolic explanation was 
investigated. Tissue was assessed for signs of an inflammatory response. Spinal cord 
sections were labelled for ED1, a microglia/macrophage marker, MHC class II and OX-42 
(CD11b), microglial markers, to explore this hypothesis. 
IV.4.1- ED1 response 
Sections were taken at the lesion site at one, two and three days after injection of VEGF, 
labelled immunohistochemically and compared with control animals. VEGF-injected tissue 
showed strong ED1 labelling localised principally within the dorsal column but also 
extending to the nearby grey matter (figure IV.8.A), indicating the presence of activated 
microglia and/or macrophages. In contrast, control tissue did not show as much ED1 
labelling. At any time point, VEGF-injected tissue revealed a significantly stronger ED1 
labelling at day one and day two following surgery (p=0.043 for both time points). 
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Figure IV.7:  A. RECA-1 labelling in spinal cords of animals treated with VEGF (right 
column) or PBS (left column) at 2 days post-surgery showing blood vessels in the 
base of the dorsal column and its surrounding grey matter. Scale: 150µm. Injections 
were made on the left side of the dorsal column. The yellow dot shows the side of 
injection. B. Density of blood vessel in the dorsal column (white matter) and the 
surrounding grey matter (grey matter) in transverse sections of spinal cord of 
animals injected with VEGF (n=6) or PBS (n=4). Error bars represent the standard 
error of the mean. 
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Figure IV.8:  A. ED1 labelling in spinal cords of animals treated with VEGF (bottom 
row) or PBS (top row) at one day (left column), two days (medium column) and 
three days (right column) post-surgery in the dorsal column. Scale: 300µm. 
Injections were made on the left side of the dorsal column. The black dot shows the 
side of injection. The bottom pictures shows a single ED1 positive cell, 
representative of the particles counted during the quantification (Scale: 20 µm)B. 
Density of ED1-positive cells in transverse sections of spinal cord of animals injected 
with VEGF (n=5) or PBS (n=3). Statistical analysis was performed with a Mann 
Whitney U test. (*: p<0.05). Error bars represent the standard error of the mean. 
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 The same trend was present at day three, although not significant. The highest amount of 
ED1 labelling was observed two days after VEGF injection and decreased at day three 
(figure IV.8.B). Moreover the presence of ED1 appeared to be side-specific in VEGF-injected 
tissue (figure IV.8.A), suggesting that macrophages are concentrated ipsilaterally to the 
injection side.  
IV.4.2- MHC-II response 
MHC-II-labelling in VEGF-injected tissue showed a broader pattern. Indeed, MHC-II could be 
found in both white matter (mainly of the dorsal column) and grey matter of the spinal 
cord: again, control tissue did not show such an intense labelling (figure IV.9.A). Similarly to 
the labelling pattern with ED1, MHC-II was mainly localised on the same side as the 
injection (figure IV.9.A) in both the dorsal column and the white matter. Also, the rounded 
shape of cells labelled (see zoomed-in panels in figure IV.9.A) with MHC-II in VEGF-injected 
tissue is a hallmark of activated microglia. In contrast, the few cells labelled in control 
tissue had ramified shape, characteristic of non-activated microglia. Quantification of the 
MHC-II-positive cells was performed through the whole spinal cord transection, specifically 
within the dorsal column and within the grey matter. The highest amount of positive cells 
was found at day two post-surgery (figures IV.9.B, IV.10.A and IV.10.B) in animals treated 
with VEGF (p=0.036 for each area analysed). The same trend, but not statistically 
significant, was observable at one day and three days following injection (figures IV.9.B, 
IV.10.A and IV.10.B). 
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Figure IV.9:  A. MHC-II labelling in spinal cords of animals treated with VEGF (bottom row) 
or PBS (top row) at one day (left column), two days (medium column) and three days (right 
column) post-surgery in the dorsal column. Scale: 200µm. Bottom left panels show a typical 
MHC-II-positive cell for each section (63x). Injections were made on the left side of the 
dorsal column. The yellow dot shows the side of injection. B. Density of MHC-II-positive 
cells in transverse sections of spinal cord of animals injected with VEGF (n=5) or PBS (n=3). 
Statistical analysis was performed with a Mann Whitney U test. (*: p<0.05). Error bars 
represent the standard error of the mean. 
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Figure IV.10:  A. Density of MHC-II-positive cells in the dorsal column of transverse 
sections of spinal cord of animals injected with VEGF (n=5) or PBS (n=3). B. Density of 
MHC-II-positive cells in the grey matter of transverse sections of spinal cord of animals 
injected with VEGF (n=5) or PBS (n=3). Statistical analysis was performed with a Mann 
Whitney U test. (*: p<0.05). Error bars represent the standard error of the mean. 
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IV.4.3- Ox-42 response 
Finally, Ox-42, a microglial receptor able to mediate activation by fibrinogen (Angelov et al., 
2009) was found sparsely in the grey matter of VEGF-injected animals but not in the control 
group (figure IV.11) at day two post-surgery, in line with both the presence of inflammatory 
markers and fibrinogen in VEGF-treated tissue. These strongly Ox-42 labelled cells had a 
round shape (a hallmark of reactive microglia (Hickey and Kimura, 1988)) compared with 
the ramified cells present in control groups suggesting activation of microglia in VEGF-
treated tissue (contrasting with the ramified inactive microglia (Hickey and Kimura, 1988)). 
IV.4.4- T-cell infiltration  
The effect of VEGF injection on T-cell infiltration was investigated two days post-surgery by 
CD3 labelling, a T-cell receptor, in tissue injected with VEGF or PBS. The labelling showed an 
absence of CD3 labelling in both the VEGF and control groups (figure IV.12) in the dorsal 
column and the grey matter, suggesting that T-cell infiltration does not occur at this stage. 
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Figure IV.12: CD3 labelling in the ipsilateral grey matter of spinal cords of animals 
treated with VEGF (right) or PBS (left) at two days post-surgery. Spleen tissue was 
used as a positive control. Scale: 20µm.  
 
 
 
Figure IV.11: OX42 labelling in spinal cords of animals treated with VEGF (right) or 
PBS (left) at two days post-surgery the ipsilateral grey matter. Scale: 20µm.  
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IV.5- Long term effect of injection of VEGF 
To assess whether injection of VEGF has any long term effect at the immunohistochemical 
level, we examined the spinal cord of animals one year after injecting VEGF or PBS. One 
year following surgery, there was no sign of IgG in the animals injected with VEGF or PBS 
(figure IV.13.A).  
 
Structural changes were assessed by looking at sections stained with H&E. No major 
change was observable when comparing sections of animals injected with VEGF or PBS. 
Specifically, no alteration was present in the motor nuclei of the ventral horn (figure IV.14). 
Moreover, the ratio between the ipsilateral and contralateral grey matter area was 
measured. Results are presented in figure IV.15. For both groups, VEGF-injected (n=6) and 
control (n=3), the ratio was very close to 1, indicating that no difference between the 
ipsilateral and contralateral side was present.  
 
Figure IV.13.B shows ED1 labelling in transverse sections of spinal cord for both the VEGF- 
and PBS- injected groups. Both pictures show the absence of ED1 in those sections, 
revealing the absence of activated microglia or macrophages in the tissue. Interestingly, 
one animal injected with VEGF presented some ED1 positive cells in the dorsal column. The 
tissue of this animal was thus investigated further, transections were taken along the cord 
to reach the caudal end (4600 µm away from the entry zone of the sciatic nerve root) and 
2200 µm more rostral from the entry zone) and labelled for ED1. As shown in figure IV.16, 
the ED1 positive cells are spread in the dorsal column in the caudal part of the cord and get 
more and more centred around the midline of the dorsal column as the sections are more 
rostral. 
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Figure IV.13:  A. IgG labelling in spinal cords of animals treated with VEGF (right) or PBS (left) 
1 year post-surgery. Scale: 600µm. Injections were made on the left side of the dorsal 
column. B. ED1 labelling in spinal cords of animals treated with VEGF (right) or PBS (left) one 
year post-surgery. Scale: 600µm. Injections were made on the left side of the dorsal column. 
The black dot shows the side of injection. 
Control VEGF 
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Figure IV.14: Motor nuclei of spinal cords stained with H&E in the ipsilateral (left) and 
contralateral (right) ventral horn one year post-surgery. Top row shows tissue treated with 
PBS. Bottom row corresponds to VEGF-injected tissue. Scale: 20µm. 
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Figure IV.15: Grey matter area ratio measured one year after surgery between the 
ipsilateral side of injection and the contralateral side of injection in PBS- and VEGF-
injected animals. Error bars represent the standard error of the mean. 
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Figure IV.16:  A. ED1 labelling in spinal cords of an animal treated with VEGF 1 year post-
surgery. Scale: 300µm. Injections were made on the left side of the dorsal column.  
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Chapter V: Results - Mechanism 
investigation 
 
V.1- Discrimination between a direct effect of VEGF and a role of the 
blood-brain barrier breakdown 
V.1.1- Motor deficit 
The results shown so far suggest that an intraspinal injection of VEGF can cause a deficit of 
the motor function of hind limbs correlated with immunohistochemical changes indicating 
inflammation associated with the injection site within the CNS. However, the origin of the 
neurological deficit is not clear. To try to determine the mechanisms underlying the deficit 
we investigated a number of potential causes, and, particularly, we aimed to determine 
whether the loss of function may be a direct action of the injected VEGF on neurons, or 
other CNS cells, or whether the loss may be due to the blood-brain barrier breakdown 
following the injection. To do so, we used a selective eNOS inhibitor, cavtratin, to block the 
blood-brain barrier breakdown induced by VEGF, while leaving other signalling pathways of 
VEGF intact. An absence of deficit following treatment with cavtratin would thus suggest 
that the locomotor alterations were due to the leakage of vascular constituents into the 
spinal cord. A preliminary study was performed only with a small number of animals 
injected with VEGF in order to assess the potential efficacy of this approach. As shown in 
figure V.1.A, no difference in the hind limb score on the horizontal test was observed 
following injection of VEGF and treatment with either cavtratin (n=4) or its scrambled 
peptide control (n=5), both groups showed a deficit compared to baseline.  
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V.1.2- Blood-brain barrier breakdown 
In view of the failure of cavtratin to prevent the loss of function, we assessed whether it 
had been effective in preventing the breakdown of the blood-brain barrier as planned.  To 
make this assessment the lesioned tissue was tested immunohistochemically for the 
parenchymal presence of IgG. As represented in figure V.1.B, IgG leakage occurred in both 
cavtratin and control peptide-treated tissue, revealing that cavtratin did not block the 
breakdown of the blood-brain barrier. Given the fact that the highest dose of cavtratin 
found in the literature was used, and the fact that it did not appear to be effective in 
protecting against blood-brain barrier breakdown, and given the high purchase price for 
cavtratin, the negative results led to the discontinuation of this part of the study. 
 
V.2- Investigation of a role of hypoxia 
V.2.1- Pimonidazole labelling  
We investigated a possible role of hypoxia in the motor dysfunction following the 
breakdown of the blood-brain barrier in animals injected with VEGF. We assessed the 
potential hypoxic state of the tissue by labelling spinal cord cross sections of pimonidazole-
treated animals for bound pimonidazole, a marker of hypoxic cells, at one, two and three 
days following surgery. As shown in figure V.2.A, a difference in pimonidazole in the grey 
matter was observable between tissue injected with VEGF and tissue injected with PBS at 
day one and two, but no labelling was present three days after injection. Control tissue did 
not show any labelling (figure V.2.A). This was confirmed by quantification of pimonidazole 
labelling intensity in the ipsilateral ventral horn (figure V.2.B). A significant difference in 
intensity was present at day one (p=0.031) and day two (p=0.026) after surgery. It is worth 
noting  
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Figure V.1: A. Relative hind limb score on the horizontal ladder test of animals 
injected with VEGF and treated with Cavtratin (n=4) or a scrambled peptide 
(n=5). Day 0 corresponds to the date of surgery. Statistical analysis was 
performed with a Wilcoxon test. (*: p<0.05) B. IgG labelling two days following 
surgery in spinal cords of animals treated with VEGF and cavtratin (left) or a 
scrambled peptide (right). Scale: 600µm. Injections were made on the left side 
of the dorsal column. The black dot shows the side of injection. 
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Figure V.2: A. Pimonidazole labelling in spinal cords of animals treated with VEGF 
(middle row) or PBS (top row) at one day (left column), two days (middle column) and 
three days (right column) post-surgery. For comparison, positive control (EAE) is 
displayed below. Scale: 150µm. Injections were made on the left side of the dorsal 
column. B. Intensity of pimonidazole labelling in the ventral horn of animals injected 
with PBS (n=3 per time point) or VEGF (n=5 per time point). Range: 0 (white) – 255 
(black). Statistical analysis was performed with a Mann Whitney U test. (*: p<0.05). 
Error bars represent the standard error of the mean. 
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that the labelling observed in VEGF-injected tissue is weaker than the labelling observed in 
the positive control tissue (spinal cord of an animal suffering from EAE) (figure V.2). The 
pimonidazole labelling observed in the grey matter of VEGF-injected tissue suggests that 
hypoxia is present in the grey matter in the first two days after injection of VEGF. 
 
V.2.2- Oxygen treatment 
We investigated further the hypothesis that hypoxia could be the cause for the motor 
deficit by attempting to reverse this deficit with an oxygen treatment. At day two following 
surgery, animals were tested on the horizontal ladder test prior to either room air or 100% 
oxygen treatment for 1h and tested once again to assess the effect of the treatment on 
their motor function. As shown in figure V.3.A, there is some variation regarding the effect 
of the treatment in different animals. 100% oxygen treatment led to an improvement of 
the motor function in some animals undergoing a deficit at day two following surgery. 
Unexpectedly, the same observation was true for some animals treated with room air 
suggesting that the repetition of the task (i.e. walking on the horizontal ladder) helped to 
improve the score the second time. On the other hand, some animals did not show any 
improvement following oxygen treatment as their score on the ladder did not improve. 
Again, the same outcome was true for animals left in room air between the two testing 
sessions. The average score within each group (room air treatment, n=5 and oxygen 
treatment, n=5) are shown in figure V.3.B. In both groups, the treatment led to an 
improvement of the motor function on the horizontal ladder test. The deficit observed in 
the group of animals treated with oxygen was stronger than for the animals treated with 
room air. This is due to chance since the protocol did not differ between the groups before 
the onset of deficit. An objective measure eliminating this bias is the percentage of deficit 
recovered after treatment (i.e. the fraction of improvement after treatment over the 
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Figure V.3: A. Relative hind limb score on the horizontal ladder test of individual 
animals injected with VEGF and treated with room air (n=5) or oxygen (n=5). 
Day 0 corresponds to the date of surgery. B. Mean relative hind limb score on 
the horizontal ladder test of animals injected with VEGF and treated with room 
air (n=5) or oxygen (n=5). Day 0 corresponds to the date of surgery. Error bars 
represent the standard error of the mean. 
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amplitude of the deficit before treatment). Oxygen treatment led to an average recovery of 
57+/-14% of the deficit and the room air treatment led to a recovery of 46+/-35% of the 
deficit. The data gathered in figure V.3 are thus inconclusive regarding the positive effect of 
oxygen on the motor deficit induced by VEGF but rather show that repetition of testing 
within a short period of time (here 1h) leads to an improvement of the ladder test score. 
 
V.2.3- HIF-1α labelling 
The pimonidazole labelling of VEGF-injected tissue was rather faint compared to the 
corresponding positive control. Combined with the failure to observe a clear effect of 
oxygen on the motor deficit induced by VEGF, this observation poses the question of 
whether the tissue injected with VEGF is really hypoxic two days following surgery. We 
explored further our hypothesis by labelling spinal cord cross-sections for HIF-1α, another 
hypoxia marker. As shown in figure V.4, a stronger labelling was present in VEGF-injected 
tissue than in control (saline-injected). This observation was confirmed in most of the 
sections observed. Indeed, HIF-1α-positive tissue was present in the dorsal column, the 
dorsal horns and the ventral horns of animals injected with VEGF. However, some of the 
VEGF-injected animals did not show stronger labelling than controls, even though these 
animals showed a deficit on the horizontal ladder test. Unfortunately, the data obtained 
from HIF-1α-labelled section is not conclusive regarding the hypothesis that hypoxia is 
present in lesions induced by VEGF. 
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Pos control Control VEGF VEGF 
Figure V.4:  HIF-1α labelling 2 days following surgery in spinal cords of animals 
treated with VEGF (middle) or PBS (right). Pictures were taken in the dorsal column 
(top) and the ipsilateral ventral horn (bottom). Positive control (EAE tissue, left) is 
shown for comparison. Scale: 150µm. Injections were made on the left side of the 
dorsal column. The black dot shows the side of injection. 
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V.3- Is nitric oxide involved in the observed motor deficit? 
We assessed iNOS expression in the spinal cords of rats treated with VEGF by labelling it 
immunohistochemically one, two and three days-post surgery. Similar results were found 
for both VEGF-injected and control groups: there was no expression of iNOS at any time 
point in any cell type of the spinal cord while the animals were exhibiting a motor deficit 
(figure V.5.A).  
 
To explore whether NO was nevertheless produced, which might then trigger a cascade of 
events, we labelled the tissue for nitrotyrosine, a product of tyrosine nitration mediated by 
reactive nitrogen species which permanently labels proteins, allowing for the detection of a 
“footprint” of NO formation at two days following surgery. No labelling could be observed 
in either of the groups (VEGF-treated and controls), confirming that NO is not involved in 
the motor deficit initiated by the injection of VEGF (figure V.5.B).  
 
V.4- Neuron excitability 
V.4.1 - EMG 
Observation of the general behaviour of animals during the different studies performed led 
to the interesting finding that at one day after VEGF injection, the hind limbs of some 
animals had tremor. It was a high frequency tremor that did not seem to affect their ability 
to perform on the different behavioural and motor tests described in Chapter 3. Following 
this observation, we investigated the excitability of neurons in the spinal cord at the site of 
injection. EMG recordings were performed on animals injected with PBS (n=6) or VEGF 
(n=7) at one day, two days and three days following surgery. Representative recordings are   
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Figure V.5: A. iNOS labelling in spinal cords of animals treated with VEGF (bottom 
row) or PBS (top row) at one day (left column), two days (middle column) and three 
days (right column) post-surgery. For comparison, positive control (EAE) is displayed 
below. Pictures of the dorsal column were taken. Scale: 150µm. Injections were made 
on the left side of the dorsal column. B. Nitrotyrosin labelling two days following 
surgery in spinal cords of animals treated with VEGF (middle) or PBS (right). Positive 
control (EAE tissue, left) is shown for comparison. Pictures of the dorsal column were 
taken. Scale: 150µm. Injections were made on the left side of the dorsal column. The 
black dot shows the side of injection. 
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shown in figure V.6. The results of this study reveal that in animals treated with VEGF, an 
increase in H/M ratio (left: p=0.043, right: p=0.043) and F/M ratio (left: p=0.043, right: 
p=0.018) is present at day one following surgery but not in control animals (figures V.7 and 
V.8). This increase was more marked on the ipsilateral side of injection than on the 
contralateral side. At day two post-surgery, the H/M and F/M ratio returned to baseline 
level for the VEGF animals and remained similar to the baseline level of control animals. At 
three days, in animals injected with VEGF, a non-significant trend towards a decrease 
(compared to baseline level was present). This was not the case in control animals. We 
then investigated which components of both H/M and F/M ratio were responsible for the 
variations observed in animals treated with VEGF. Figures V.9, V.10and V.11 show the 
individual H reflex, F response and M response respectively of each animals involved in the 
study. The M response did not show any consistent pattern of change for most of the 
animals but both the H reflex and F response followed the same pattern as the H/M ratio 
and F/M ratio respectively, leading to the conclusion that both H reflex and F response are 
affected by the injection of VEGF. 
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Figure V.6: Representative recordings of an H reflex (top) and an f-wave 
obtained at the maximal M response (bottom). Stimulus was sent at a 2 ms 
latency after the beginning of the recording. 
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Figure V.7: H/M ratio recorded in the left (top) and right (bottom) foot muscle 
in animals injected with PBS (n=5) or VEGF (n=7). Day 0 corresponds to the date 
of surgery. Statistical analysis was performed with a Wilcoxon test. (*: p<0.05) 
Error bars represent the standard error of the mean. 
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Figure V.8: F/M ratio recorded in the left (top) and right (bottom) foot muscle in 
animals injected with PBS (n=5) or VEGF (n=7). Day 0 corresponds to the date of 
surgery. Statistical analysis was performed with a Wilcoxon test. (*: p<0.05) 
Error bars represent the standard error of the mean. 
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Figure V.9: H reflex amplitude recorded in the left (top) and right (bottom) foot 
muscle of individual animals injected with PBS (n=5) or VEGF (n=7). Day 0 
corresponds to the date of surgery.  
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Figure V.10:  F response amplitude recorded in the left (top) and right (bottom) 
foot muscle of individual animals injected with PBS (n=5) or VEGF (n=7). Day 0 
corresponds to the date of surgery.  
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Figure V.11: M response amplitude recorded in the left (top) and right (bottom) 
foot muscle of individual animals injected with PBS (n=5) or VEGF (n=7). Day 0 
corresponds to the date of surgery.  
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V.4.2- Synaptic markers 
Following these observations, we investigated whether changes in synaptic properties were 
responsible for these changes in excitability. We thus looked at the expression of 
synaptophysin and PSD-95, respectively a pre-synaptic and a post-synaptic marker, two 
days following surgery. Figure V.12 shows a typical image obtained from double-labelling 
for synaptophysin and PSD-95 in the ventral horn, where motor neurons are located. An 
interesting observation is that synaptophysin is broadly expressed in the grey matter, and 
not only around motor neurons. Also, PSD-95 is more localized in clusters which are not 
only present around motor neurons, but also on other cells in the grey matter. Neuron cell 
bodies that are not located in the motor nuclei of the ventral horn are positive for PSD-95 
within their cytoplasm whereas motor neurons of the motor nuclei are not. It has been 
shown the ventral horn and dendrites in the adjacent white matter develop synaptic 
pathology in EAE (Zhu, 2003). We therefore looked at the expression pattern of 
synaptophysin and PSD-95 in the ipsilateral ventral horn and the white matter lateral to the 
horn column where motor neurons develop their dendrites. No difference could be 
observed between tissue injected with VEGF and tissue injected with PBS (figure V.13),  
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Figure V.12: Representative labelling of the ventral horn for PSD-95 (left panel, 
green), synaptophysin (middle panel, red) and the merged pictures (right panel). 
Colocalization of PSD-95 clusters with synaptophysin positive tissue was present 
around the motor neurons of the motor nuclei (filled arrow head) but also elsewhere 
in the tissue (empty arrow heads), possibly on other cell types. Cell bodies of motor 
neurons out of the motor nuclei had their cytoplasm PSD-95-positive (arrow). Scale 
bar: 10µm. 
PSD-95 Syn Merge 
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Figure V.13: Synaptophysin and PSD-95 labelling in the ventral horn (synaptophysin 
and PSD-95) and adjacent white matter (synaptophysin) in VEGF and control 
animals at one day and two days following surgery. Scale bar: 10µm. 
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suggesting that synapses pathology is not responsible for the deficit observed two days 
following injection of VEGF. 
 
V.5- Astrocyte activation induced by injection of VEGF  
We investigated whether injection of VEGF into the spinal cord had detectable effects on 
astrocytes, as detectable by their expression of GFAP. In a time course study, spinal cord 
sections of animals injected with VEGF or PBS were labelled for GFAP, an astrocytic marker. 
Different areas of the spinal cord were assessed, namely the dorsal column, dorsal horns 
and ventral horns. Sections of animals injected with VEGF showed a more intense labelling 
compared to control animals injected with PBS, as shown in figure V.14. GFAP intensity was 
higher in all areas investigated at day one and two following surgery. Labelling on sections 
taken three days after surgery was similar to the labelling observed in control tissue. 
Interestingly, the ipsilateral side was more strongly labelled compared to the contralateral 
side. In VEGF-treated animals, astrocytes marked with GFAP were ramified with long and 
thick processes. 
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Figure V.14:  GFAP labelling in spinal cords of animals treated with VEGF (right column) 
or PBS (left column) at one day (top row), two days (middle row) and three days (bottom 
row) post-surgery. Pictures were taken in the left dorsal horn (top left panel), the dorsal 
column (top middle panel), the right dorsal horn (top right panel), the left ventral horn 
(bottom left panel) and the right ventral horn (bottom right panel). Scale: 10µm. 
Injections were made on the left side of the dorsal column. 
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Chapter VI: Discussion 
 
The findings reveal that an intraspinal injection of VEGF provoked a breakdown of the 
blood-brain barrier localised to the injection site. The barrier dysfunction was present at 24 
hours, and persisted for two days. On the first day after injection, there was an increase in 
neuronal excitability, which returned to normal within 24 hours. On the second day there 
was an obvious neurological deficit, consisting of a spastic weakness of the hindlimbs, with 
a tendency for the ipsilateral limb to be more profoundly affected. The loss of motor 
function was accompanied by a reduction in sensory function consisting of a decrease in 
sensitivity as assessed by von Frey stimulation. The motor and sensory deficits were 
significant, but expressed for only one day. Histochemical studies showed that 
inflammation (as revealed by the presence of macrophages and activation of microglia and 
astrocytes) correlated both temporally and spatially with the breakdown of the blood-brain 
barrier. During this time the tissue suffered from hypoxia, as determined by an increase in 
binding of systemically-administered pimonidazole. The gross structure of the parenchyma 
remained unchanged and there was no evidence of demyelination or degeneration. 
 VI.1- Characterization of the blood-brain barrier breakdown 
VI.1.1- IgG leakage 
We found that the intraspinal injection of VEGF at the T13-L1 vertebral level caused blood-
brain barrier breakdown as assessed by IgG leakage at days one and two post-surgery. A 
similar observation had been made by Benton and Whittemore (Benton and Whittemore, 
2003) except that they found that the peak of leakage was on the first day following 
injection of VEGF, although we could not distinguish an obvious difference between days 
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one and two. This may be due to the difference in method used to assess the leakage of 
blood components into the CNS. Whereas Benton and Whittemore used horseradish 
peroxidase (HRP) injected intravenously, we measured the leakage of IgG, which has a 
different molecular weight (150kDa compared with 44kDa for HRP), but may also have 
different properties when considering the blood-brain barrier. Moreover, we used rat VEGF 
whereas the other group used recombinant human VEGF, which may have a different 
potency in terms of blood-brain barrier disruption. Consistently, the blood-brain barrier 
was repaired three days after the injection. IgG was found mainly in the grey matter, 
consistent with the greater density of blood vessels in the grey vs. the white matter. Also, 
IgG was present throughout the whole spinal cord cross-section, and not only around the 
dorsal column where VEGF had been injected. It is not clear from the current study 
whether the VEGF diffuses away from the dorsal column to affect blood vessels across the 
spinal cord, or whether the IgG diffuses from the dorsal column into the surrounding tissue. 
Rather than focus on this issue we have studied the mechanism leading to the deficit, once 
the lesion had been characterized both immunohistochemically and functionally. In any 
case, this observation means that the blood components entering the CNS after injection of 
VEGF can interact with the CNS cells in any part of the spinal cord and are able to influence 
many pathways. Moreover, at day three post-surgery, most IgG has disappeared but the 
base of the dorsal column consistently revealed some positive labelling in animals injected 
with VEGF. This suggests that a higher concentration of IgG is present at this location and 
takes longer to be removed or that the blood barrier is still open at day three. The latter 
possibility is unlikely since it is known that VEGF-induced blood-brain barrier stops after 
72h (Benton and Whittemore, 2003).  
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VI.1.2- Fibrinogen extravasation 
MS lesions show a transient blood-brain barrier breakdown characterized by leakage of 
fibrinogen (Kermode et al., 1990; Kirk et al., 2003). We investigated this feature of MS 
lesions in our model and showed that intraspinal injection of VEGF leads to fibrinogen 
extravasation into the CNS, confirming the observation that a blood-brain barrier 
breakdown occurs. This is in line with other studies showing that direct injection of VEGF 
into the retina leads to a breakdown of the blood-retina barrier, and, therefore, fibrinogen 
leakage into the retina (Hofman et al., 2000). Similarly to IgG, fibrinogen was present in the 
whole section, in the grey matter and the dorsal column. Less fibrinogen was present at 
day three, suggesting that some of the fibrinogen that leaked during the first two days had 
been removed.  
 
VI.1.3 Evans blue leakage 
The last marker we used to assess the blood barrier leakage was Evans blue. Evans blue 
leakage was apparent around the injection site, delimitating a lesion 6mm in length along 
the spinal cord, similar to other studies (Sasaki et al., 2010). The lesion induced is large 
enough to affect the spinal roots leading to the sciatic nerve, which enter the spinal cord in 
the same area (Gelderd and Chopin, 1977). This anatomical proximity provided the basis for 
our study of hind limb motor function.  
 
Leakage of Evans blue was observed two days following the injection of VEGF but it was not 
studied at days one and three due to limited animals available at these time points (since a 
clear focus was made on the second day for immunohistochemical studies). As it can be 
argued that the presence of IgG in the spinal cord may be due to an immunological 
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activation, we are aware of the necessity to characterize further the blood brain barrier 
breakdown at other time points (namely one and three days) thanks to specific markers 
such as Evans blue or HRP, as done in another study (Benton and Whittemore, 2003). HRP 
would allow a better localisation of the leakage compared to Evans blue, as it can be 
precisely localised via immunohistochemical labelling. Moreover, using such a marker at 
different time points would confirm the timing of the blood brain barrier leakage we 
observe and increase the consistency we obtain using IgG and fibrinogen labelling. 
 
Overall, an intraspinal injection of VEGF is able to induce a focal breakdown of the blood-
brain barrier, thus allowing for the selection of particular parts of the body by choosing the 
site of injection along the spinal cord. Interestingly, the breakdown was also delimitated in 
time. Both these characteristics are similar to what has been observed in brains of patients 
with MS lesions (Cotton et al., 2003; Kermode et al., 1990; Kirk et al., 2003; Leech et al., 
2007). Since no symptom is present before the plasma leakage into the CNS (Kermode et 
al., 1990), inducing a leakage in naive animal is relevant to understand the pathogenesis 
leading to MS symptoms. 
 
VI.2- Characterization of the motor deficit induced by VEGF 
VI.2.1- Effect of VEGF injection on trained walking ability 
We investigated the functional consequences of an injection of VEGF in the spinal cord by 
testing the animals on the horizontal ladder test, as described elsewhere (Metz and 
Whishaw, 2009). Animals injected with VEGF showed a motor deficit in hind limb function 
two days following surgery, and recovered the next day. This result is comparable with 
Sasaki and colleagues’ observations, i.e. animals intraspinally injected with VEGF show a 
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deficit in the next three days after injection (Sasaki et al., 2010). We believe that Sasaki and 
colleagues misinterpreted their finding in that they attributed the deficit to the surgical 
trauma associated with the injection (even though no control group was used for 
comparison).  
 
In the current study, some animals were tested for up to a year following the injection and 
no deficit could be observed after the two day time point. The blood-brain barrier 
breakdown induced by VEGF follows a similar timing. It is present the first two days 
following surgery and stops at day three. This correlation suggests that the barrier leakage 
in the CNS may have a role in the motor deficit observed. Moreover, both hind limbs were 
affected by this motor impairment, as expected given that blood components (IgG and 
fibrinogen) were present across the whole width of the spinal cord, despite the injection 
being made on the left side of the dorsal column. Thus although each side of the spinal 
cord primarily controls the ipsilateral hind limb (Nicolopoulos-Stournaras and Iles, 1983), 
the blood components affected both sides of the cord. 
 
VI.2.2- Effect of VEGF injection on response to tactile stimuli 
We investigated the effect of injection of VEGF on nociception. We showed that animals 
injected with VEGF had a significantly reduced sensitivity in their hind paws at day two 
following surgery. This result correlates temporally with the motor deficit. The pathway for 
innocuous and noxious sensations is mediated by neurons in the dorsal horns (Christensen 
and Hulsebosch, 1997; Giesler and Cliffer, 1985), and although VEGF is injected into the 
nearby dorsal columns, its effects are known to spread to the nearby dorsal horns, as 
evidenced by the presence of IgG and fibrinogen in this part of the grey matter. It thus can 
be inferred that the alterations in sensory function occur mainly at the lesion site in 
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response to the barrier breakdown. Interestingly, this desensitization was stronger on the 
ipsilateral side, suggesting that even though no side-specificity was observed with the 
horizontal ladder test, a slight sensory difference is present. The strength of the tactile 
stimuli applied to the hind paws of the animals are above the threshold for nociception. 
The results presented here therefore suggest that animals injected with VEGF are 
hypoallergesic. However, it must be borne in mind that the same animals show signs of 
motor dysfunction. Thus, the decreased sensitivity to tactile stimulation could simply be 
due to weakness in the hind limbs which prevents the animals from lifting their paw. 
 
VI.2.3- Effect of VEGF injection on natural behaviour 
Rats, amongst other species such as mice, gerbils or hamsters, have a natural tendency to 
burrow. We exploited this ability to assess any difference in natural behaviour between 
control animals and animals injected with VEGF, as described by Deacon (Deacon, 2006, 
2009). After a period of adaptation to the new enriched environment, all of the animals 
burrowed to eject 100% of the woodchip bedding when left with a burrowing tube 
overnight. Animals injected with VEGF displayed a reduced burrowing activity (only 50% of 
the woodchip bedding was ejected) for the first three days following surgery. Although the 
first two days of reduced activity correlate well with the motor deficit observed, the 
decreased in burrowing activity at day three was not expected, since the motor functions 
are restored at this point. We suggest that at three days, the motor deficit was not severe 
enough to be detected by observation, but it was nevertheless sufficiently strong to 
prevent normal burrowing activity. Another possible explanation is that the animals had 
sufficient motor power to eject the woodchips, but were not motivated to do so. One 
potential reason for a lack of motivation may be loss of visceral motor function and, for 
example, stomach cramps.  
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VI.2.4- Effect of VEGF injection on hind-limb strength 
The inclined plane test was originally conceived to evaluate the consequences of spinal 
cord injury on motor functions (Rivlin and Tator, 1977), and it can be used as an index of 
animal strength (Gale et al., 1985; von Euler et al., 1997). We assessed hind limb strength 
by placing the animals on the inclined plane facing upward, although it is possible to place 
them in different orientations (Pearse et al., 2005). In our model, animals injected with 
VEGF were unable to maintain their position on the inclined plane from a lower angle 
compared to their control counterparts, confirming the presence of a motor deficit. 
Similarly to the horizontal ladder test, and the time course of blood-brain barrier 
breakdown, the deficit on the inclined plane appeared at two days following surgery and 
disappeared the following day. 
 
VI.2.5- Effect of VEGF injection on positioning of the tail 
While analysing the locomotor properties of animals on the horizontal ladder test, it was 
noticeable that animals injected with VEGF were not able to lift their tail in a natural 
manner while walking, as naive animals can. We therefore measured the tail angle from 
videos taken during the ladder test. We observed that animals injected with VEGF were 
dragging their tail, leading to an angle of 0° compared to baseline. The tail is controlled at 
the low sacral level (S2) of the spinal cord (Bennett et al., 1999), which is located under the 
L2-L3 vertebrae. Although the VEGF lesion was induced more rostrally, it is likely that more 
caudal functions will still be affected as the pathways responsible for voluntary tail function 
have first to pass through the injected region. Thus in a manor analogous to spinal cord 
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injury, a lesion in the thorax can cause loss of tail reflex in cats (Cavallari and Pettersson, 
1989).  
 
VI.2.6- Effect of VEGF injection on gait 
Gait analysis is useful to quantify locomotor behaviour in an objective manner thanks to an 
automated data analysis system. Such systems also allow control of the inter-animal 
variability in walking speed. Using the Treadscan system as described elsewhere (Beare et 
al., 2009), we quantified several gait parameters of animals injected with VEGF. The 
outcome of this study was a non-significant but consistent trend towards an impairment in 
balance and posture at day two following surgery, only in animals injected with VEGF. 
Indeed, animals injected with VEGF showed a decrease in rear track width and gait angle at 
day two post-surgery, indicative of a lack of balance and altered posture: the paws were 
positioned closer to the longitudinal midline. Stride frequency and stance time were 
reduced while minimal longitudinal reach and feet base were increased. This shows that 
the animals injected with VEGF were making smaller steps at a higher frequency to 
maintain their speed. This can also be indicative of balance problems, since smaller and 
faster steps help maintain balance, but it could also come from an inability to perform 
bigger steps because of a motor impairment. The analysis performed in this study does not 
allow for the discrimination between the two hypotheses since both of them are 
interrelated. 
 
VI.2.7- Complementarity of behavioural tests 
In accordance with Muir and Webb’s view on the implementation of behavioural tests 
(Muir and Webb, 2000), we performed a comprehensive analysis with functional tests 
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including three components: a measure of motor abilities during trained behavioural tasks 
(ladder test, tail angle), a measure of motor abilities during spontaneous locomotion 
(treadmill, inclined plane, burrowing) and an assessment of reflex function (von Frey hair 
test). Overall, the different behavioural and locomotor tests all lead to the same 
observations and bring complementary conclusions. At day one following surgery, a hint of 
motor deficit is present in animals injected with VEGF and is detectable using the 
burrowing and tail-angle test. However, this deficit is not yet strong enough to be revealed 
by other tests. At day two, all tests reveal a significant deficit which has a locomotor 
component (inclined plane, ladder test) linked to a problem in balance and posture 
(treadmill, tail angle). Finally, the sensory motor pathway seems also to be altered (von 
Frey). All these impairments lead to a modification in general behaviour, as assessed by the 
burrowing activity test. Most functions recovered at day three, although the burrowing 
activity was not restored at this time point, suggesting that impairments not detectable 
with other tests may still be present.  
VI.3- Discrimination between a direct action of VEGF on the CNS 
tissue, and the consequences of blood-brain barrier leakage 
It is thought that VEGF can have a direct effect on the CNS independently of its effect on 
the blood brain barrier. Indeed, VEGF has a trophic role on the neuronal cell population. It 
can enhance neuronal survival and neurite outgrowth in the brain cortex and the 
substantia nigra (Rosenstein et al., 2003; Silverman et al., 1999) and in cultured dorsal root 
ganglia (Sondell et al., 1999; Sondell et al., 2000). VEGF also protects neurons during 
hypoxia (Jin et al., 2000b) and glutamate-induced excitotoxicity (Matsuzaki et al., 2001). 
However, it is not yet clear whether these effects are due to a direct action of VEGF 
(Rosenstein et al., 2010) or whether it is acting indirectly, perhaps through glia (Krum et al., 
2002).  
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To distinguish between direct and indirect effects of VEGF on neurons we have sought to 
inhibit its indirect effects (i.e. effects on the blood-brain barrier) to determine whether the 
loss of function persisted. It has been shown that VEGF exerts its vascular permeability 
action via eNOS (Argaw et al., 2012), an enzyme selectively expressed in endothelial cells. 
Specific inhibition of this pathway is thus a good opportunity to prevent the blood-brain 
barrier leakage while allowing any potential direct action of VEGF on other cell types and 
thereby to discriminate between the two hypotheses described earlier. Cavtratin, a cell-
permeable fusion protein made from caveolin-1, selectively blocks eNOS without affecting 
other isoforms of the enzyme (Bernatchez et al., 2005; Bucci et al., 2000; Gratton et al., 
2003). It had previously been shown in mice that blood-brain barrier breakdown induced 
by direct microinjection of VEGF in the brain was abrogated by peripheral injection of 
cavtratin at a dose of 2.5 mg/kg (Argaw et al., 2012). In another study, 1 mg/kg was able to 
reduce vascular permeability induced by inflammation (Bucci et al., 2000; Hatakeyama et 
al., 2006). Studies involving cavtratin injections in rats have also been published (Bauser-
Heaton et al., 2008; Li et al., 2009) but none of them concerned vascular permeability. 
Given this lack of experience in rats and the high purchase price of cavtratin (and its 
scrambled peptide control), we decided to conduct a preliminary experiment based on the 
highest dose we found in the literature (2.5 mg/kg i.p. every 24h) in order to optimize the 
chances of successful inhibition of blood-brain barrier breakdown. Unfortunately, the 
animal group injected with cavtratin displayed a similar deficit and similar IgG leakage 
following VEGF injection as the group injected with the scrambled peptide, so the cavtratin 
appeared ineffective in our model. Despite this disappointing outcome in pilot 
experiments, we believe on the basis of the published work that this pharmacological 
method may be a good tool to investigate the events leading to the motor deficit we 
observed, and thus that a pharmacokinetic study would help in finding an effective dose in 
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blocking the blood vessel leakage. This would however be a very expensive method and we 
decided to stop this study and investigate other pathways. Although we know that VEGF 
can act directly on neurons, there is no literature suggesting the presence of negative 
actions that could explain the loss of function that we observe. On the contrary, it has been 
extensively documented that VEGF can have positive actions on neurons, acting as a 
trophic factor and promoting growth and survival. Although it obviously needs further 
investigation; the latter observation points towards an indirect role of VEGF in the deficit 
we observe, reinforcing the hypothesis that it is caused by breakdown of the blood-brain 
barrier. 
VI.4- Structural changes induced by injection of VEGF 
VI.4.1- Oedema 
Blood-brain barrier leakage in the CNS often leads to the formation of oedema. In patients 
with spinal cord injury, it has been shown that the magnitude and extent of oedema 
following injury correlates with the severity and extent of recovery from the motor deficit 
(Flanders et al., 1999). In our model, the time course of blood-brain barrier breakdown 
correlates strongly with the temporal course of the neurological deficit and the following 
recovery, suggesting that it may be causally related to the motor deficit. In animals with 
EAE, an animal model of MS, the blood-brain barrier is altered and this leads to oedema 
formation and exacerbation of symptoms (Claudio et al., 1990). Since the course of disease 
in EAE is made of acute phases of motor deficit during which severe oedema occurs 
(Kaneyama et al., 2013), we investigated whether, in our model of acute motor deficit 
followed by remission, such oedema was present during the blood-brain barrier 
breakdown. We discovered that no oedema was present at the time of functional deficit 
undergone by animals injected by VEGF, suggesting that the leakage of blood components, 
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as confirmed by the presence of IgG and fibrinogen, was not large enough to induce any 
oedema that could be seen directly on toluidine blue-stained spinal cross-sections. The 
hypothesis suggesting that oedema is the cause of the functional deficit can thus be 
discounted. 
 
VI.4.2- Demyelination and axonal loss 
In EAE, animals typically experience a relapsing-remitting onset during which they undergo 
one or more acute peaks of disease, before they enter a more chronic phase during which 
disabilities persist or increase progressively. Similar phenomena occur in MS. During the 
acute phase, inflammation is thought to be primarily responsible for the symptoms 
observed, whereas demyelination and axonal loss are the primary causes of the progressive 
impairments seen in the chronic phase (Wujek et al., 2002). Accordingly, during the acute 
deficit we observe in our model, we did not see any axonal loss or demyelination in spinal 
cords injected with VEGF, consistent with the rapidly evolving but also rapidly reversing 
deficit.  
 
This absence of demyelination in the VEGF model is in contrast to the presence of this 
pathology when LPS is injected into the spinal cord (Felts et al., 2005; Marik et al., 2007), 
despite the fact that in both cases there is breakdown of the blood-brain barrier following 
the injection. However, the duration of the blood-brain barrier deficit is longer (more than 
five days) in the LPS lesion, resulting in prolonged inflammation and plasma protein 
deposition in the CNS (Felts et al., 2005; Marik et al., 2007), and this is followed by 
demyelination after two days. We suggest that the intensity of the VEGF lesion, and the 
limited duration of plasma leakage induced by VEGF (two days) is not long enough to 
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trigger any axonal loss or demyelination within one month, nor indeed within one year, as 
revealed in our long-term study. 
 
VI.5- Possible role of hypoxia 
It has been shown in our lab (Davies et al., 2013) that hypoxia is linked to the neurological 
deficits observed in the acute phase of EAE. Indeed, pimonidazole labelling and spinal cord 
tissue oxygen concentration were both strongly correlated with the severity of the disease 
in animals with EAE. We have therefore considered whether hypoxia may also play a role in 
the loss of function following VEGF injection. We found that, in VEGF-injected tissue (but 
not in PBS-injected control tissue), the grey matter was positive for pimonidazole, although 
to a lesser extent than in the EAE tissue used as a positive control. This labelling was 
present at days one and two following surgery but not at day three, so the presence of 
hypoxia correlated temporally with the expression of deficits. We investigated whether the 
hypoxia may be responsible for the loss of function by attempting to reverse the hypoxia by 
the administration of inspired oxygen, i.e. normobaric hyperoxia. Indeed, Davies et al 
treated animals suffering of EAE for 1h with 95% oxygen and saw an improvement of 
neurological score in the animals treated with oxygen compared to the ones treated with 
room air. In our model, after 1h of oxygen treatment, most of the animals showed some 
improvement on the horizontal ladder test. However, the same was true for the animals 
treated with room air. These findings thus suggest that the improvement in function was 
due to practise rather than therapy, i.e. that the animals were performing better simply 
because of the short period of time separating the two trials on the horizontal ladder. Since 
the amplitude of improvement was similar for both the room air and the oxygen group, we 
concluded that normobaric hyperoxia does not improve the clinical deficit observed in 
animals injected with VEGF.  
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We decided to use a second marker of hypoxia to confirm the hypoxic state of the tissue at 
the time of deficit. Using HIF-1α immunolabelling, we showed that this transcriptional 
inducible factor was expressed at day two after injection, consistent with the (seemingly 
more sensitive) pimonidazole result suggesting that the tissue of animals injected with 
VEGF is hypoxic. HIF-1α was labelled in the dorsal column, the dorsal horn and the ventral 
horn (mainly in motor neurons). However, not all sections of animals injected with VEGF 
and showing a neurological deficit illustrated this labelling. Thus, the HIF-1α expression is 
not necessarily correlated with the deficit we observe, suggesting that hypoxia, which 
induces HIF-1α expression, is not always present when the animals suffer from a functional 
deficit. However, for these animals, pimonidazole labelling was present, highlighting a 
partial discrepancy between the two hypoxia markers which is best explained by a different 
sensitivity of their expression.  
 
Although the findings with pimonidazole can potentially explain the neurological deficit 
observed, it is wise to be cautious before accepting this explanation: i.e. the possibility that 
the labelling is simply an artefact must be considered. First to consider is the possibility that 
more pimonidazole passes into the tissue when the blood-brain barrier is disrupted, i.e. 
that pimonidazole is normally only sparingly permeable across the intact blood-brain 
barrier. This remains a concern, but against it must be balanced the fact that, according to 
the relevant literature, pimonidazole will not bind to tissue irrespective of its 
concentration, unless the oxygen concentration is low. If so, then an increased 
pimonidazole concentration is not only speculative, it is also irrelevant. Another potential 
artefact can also be discounted by similar argument. Thus there is a potential concern that 
haem-iron complexes present in blood can prevent the oxidation of pimonidazole into its 
oxygen-insensitive N-oxide metabolite (Walton et al., 1985). Potential leakage of haem-iron 
  
170 
 
complexes into the CNS following disruption of the blood-brain barrier may therefore 
increase the concentration of detectable pimonidazole within the tissue, but if the 
pimonidazole concentration is partly irrelevant, this concern is diminished. Also, 
inflammatory cells, which are present in the spinal cord of animals injected with VEGF, may 
produce nitroreductases which are enzymes capable of reducing pimonidazole in an 
oxygen-insensitive manner, thus leading to hypoxia-independent labelling. The presence of 
inflammatory cells could therefore provide a false positive labelling of pimonidazole in 
VEGF-injected spinal cord compared with control tissue. This complication remains a 
theoretical concern in the brain, but the issue has been directly addressed in the liver 
(Arteel et al., 1995) where it has been shown that the presence of nitroreductase enzymes 
does not affect pimonidazole labelling, which seems to be solely dependent on the oxygen 
gradient.  
 
We used several methods to assess whether hypoxia caused the functional deficit we 
observe, but none of them provided a clear answer. At least three hypotheses are 
consistent with the data. 
 
1. The tissue is not hypoxic, which explains why the oxygen therapy is ineffective. In 
this case the pimonidazole labelling is an artefact (potential mechanisms have been 
discussed above). The labelling for HIF-1α, when present, would also be an artefact, 
perhaps induced by a non-hypoxic pathway. 
 
2. Hypoxia is present but not very severe, yet its effects are slowly cumulative so that 
over two days it results in a functional deficit. This would explain the mild 
pimonidazole labelling at one day, which correlates with a weak, non-significant 
neurological deficit, but accumulating over two days to produce a significant 
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deficit. Such a low level of hypoxia may not be sufficient to induce the strong 
expression of HIF-1α, hence the variability of HIF labelling in animals injected with 
VEGF. However, if this explanation is correct, oxygen treatment would be expected 
to result in an alleviation of neurological deficit, which did not occur. 
 
3. Hypoxia is sufficiently severe to induce labelling by pimonidazole, but this severity 
is insufficient to cause a loss of function. Such borderline hypoxia would explain the 
variability in HIF-1α expression, and also the inability of oxygen treatment to 
reverse the neurological deficit.  
Further investigation is needed to confirm or refute any of these hypotheses. However, it is 
notable that the normal spinal cord does not label for hypoxia and has normal function, 
that the VEGF lesion labels lightly for hypoxia and has partial function, and the EAE spinal 
cord labels strongly for hypoxia and has no function. In this view, the hypoxia in the VEGF 
lesion falls on a continuum of loss of function.  
 
VI.6- Potential triggers of inflammation 
An interesting feature of our model is the presence of inflammatory cells (ED1-positive 
macrophages, MHC-II-positive microglia and Ox-42-positive microglia) within the spinal 
cord of animals presenting a hind limb motor deficit. We can confidently infer that this 
inflammatory reaction is not due to the surgical trauma caused by the injection since 
control animals show no inflammation despite experiencing the injection. Several 
hypotheses can explain the inflammation within the CNS.  
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VI.6.1- VEGF 
It is known that via VEGFR-1 expressed on monocytes and macrophages, VEGF plays a role 
in the activation (Clauss et al., 1996; Sawano et al., 2001) and recruitment of inflammatory 
cells (Bottomley et al., 2000; Lemstrom et al., 2002; Luttun et al., 2002). Accordingly, VEGF 
is upregulated in inflamed tissues and provides recruitment signals for the infiltration of 
inflammatory cells, and inhibition of the VEGFR-1 pathway diminishes inflammatory cell 
infiltration and reduces the production of pro-inflammatory cytokines (MCP-1, TNF-α) by 
macrophages (Luttun et al., 2002). VEGF can thus directly stimulate an inflammatory 
process that could have deleterious consequences and trigger the deficit we observe.  
VI.6.2- Fibrinogen, thrombin and albumin 
Another hypothesis explaining the presence of inflammation in animals injected with VEGF 
is the abnormal presence of blood proteins in the CNS following breakdown of the blood-
brain barrier. It has been shown that fibrinogen can directly activate macrophages 
(Akassoglou et al., 2004; Sobel and Mitchell, 1989) such that it stimulates chemokine 
secretion by these cells at sites of inflammation (Smiley et al., 2001). Pharmacologic 
depletion of fibrinogen also decreases inflammation in a mouse model of MS (Akassoglou 
et al., 2004). The presence of fibrinogen we observe in VEGF-injected tissue and the 
correlation with the inflammation we observe suggest that fibrinogen will contribute to 
inflammatory cell activation and infiltration.  
 
Thrombin may also be involved in the induction of an inflammatory response as intra-
cortical injection of thrombin induces microglial activation (Lee da et al., 2006; Moller et al., 
2000) that can be inhibited with anti-inflammatory agents (Choi et al., 2005a). It is thus 
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possible that the presence of thrombin following the blood-brain barrier leakage, if shown, 
may trigger the inflammatory response we observe.  
 
Albumin is another plasma component that can lead to microglial activation, inducing the 
release of pro-inflammatory cytokines such as IL-1β (Ralay Ranaivo and Wainwright, 2010) 
or TNF-α (Hooper et al., 2009). 
 
In summary, the presence of each of these vascular factors in the parenchyma can promote 
inflammatory changes.  
 
VI.6.3- Does inflammation play a role in the functional deficit 
The presence and magnitude of the inflammatory changes correlates quite precisely with 
the expression of neurological deficit, implying that the inflammation and deficit may be 
causally related. Moreover, inflammation as revealed by ED1-positive cells is most severe in 
the side ipsilateral to the injection, which correlates with the ipsilateral expression of 
deficit. The dorsal cord is involved in proprioception (Jordan and Schmidt, 2002) and 
accordingly the desensitization of the hind paw was stronger on the ipsilateral side.  
 
VI.6.4- Nitric oxide 
NO is a potent cause of mitochondrial dysfunction (Witte et al., 2010) and activated 
microglia can produce abundant NO (and hence loss of excitability) via the induction of 
iNOS (Galea et al., 1992). However, we found that iNOS was not expressed at the injection 
site during at least the three days following surgery, indicating that NO plays no role in the 
loss of function. However, to ensure that other sources of NO may not be playing a role, we 
  
174 
 
labelled for nitrotyrosine as a “foot print” of the earlier presence of peroxynitrite, formed 
when NO combines with superoxide. However, as with iNOS, no nitrotyrosine was present 
in either VEGF-injected or PBS-injected tissue. We therefore conclude that microglia-
induced NO does not play a role in the functional deficit we observed.  
 
VI.6.5- T-cells 
T-cells can express VEGFR-2 in inflammatory conditions and VEGF action via this receptor 
can lead to a pro-inflammatory Th1 phenotype (Mor et al., 2004). It has also been shown 
that VEGF is functional for CD-3-positive lymphocyte recruitment (Reinders et al., 2003). 
We therefore investigated whether an intraspinal injection of VEGF could lead to CD-3 
positive lymphocyte entry into the CNS, in conjunction with the inflammatory pattern we 
observed. No T-cell could be found in the spinal cord injected with VEGF, at any time point. 
This result contrasts with the involvement of T-cells in EAE pathogenesis, where they 
contribute to the tissue damage observed (Gold et al., 2006). However, even though 
chronic and acute MS lesions show T-cell infiltration (Stadelmann et al., 2011), it has also 
been shown that some early lesions are devoid of T-cell infiltration (Barnett and Prineas, 
2004). Thus, it is possible that the lesion we induced with the injection of VEGF possesses 
the characteristics of early pre-demyelinating lesions that could be induced by vascular 
abnormalities such as a blood-brain barrier breakdown (Ge et al., 2008). 
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VI.7- Hyperexcitability 
VI.7.1- Change in H/M and F/M ratio 
During the behavioural testing of the animals it was noticed that one day following surgery, 
in absence of any deficit, the animals injected with VEGF presented an unexpected tremor 
in the hind limbs, indicating a change in motor neuron excitability. We confirmed this 
possibility by showing an increase in H/M and F/M ratios at one day post-surgery, and this 
change returned to normal at day two, when the deficit was present. Only the H and F 
components of these ratios were increased, while the M response did not show any 
consistent change. This observation was expected since the M response is the direct 
response to stimulation, and the pathway does not involve the spinal cord. Moreover, 
changes in M response such as temporal dispersion or decreased amplitude are hallmarks 
of demyelination or axonal neuropathy respectively (Argyriou et al., 2010). An absence of 
change is thus in line with our findings that neither demyelination nor axonal loss occur in 
our model. On the other hand, both H and F signals pass through the VEGF-lesioned part of 
the spinal cord (one via the sensory pathway located in the dorsal horn, the other through 
the cell body of the motor neurons located in the ventral horn) explaining the EMG results 
obtained.  
Care must be taken in the interpretation of EMG data, especially the F-wave parameters. 
Indeed, a controversy is still on-going as to whether F-wave measurements are good 
indicators of motor neurons excitability. Several studies have suggested that a reduction of 
the incidence of F-waves can be obtained by both an increase and a decrease in motor 
neuron excitability (Espiritu et al., 2003; Hultborn and Nielsen, 1995) whereas others 
consider the study of the recurrent discharge produced by the F-wave as a valid mechanism 
to assess motor neuron excitability (Rossi et al., 2012; Salih et al., 2011). Several 
hypotheses can explain this discrepancy between the F-wave parameters and motor 
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neuron excitability. It has been suggested (Burke, 2014) that the supramaximal stimulus 
used to study F-waves can also elicit a Ia afferent signal that triggers an H-reflex mediated 
response in the low-threshold motor neurons. Therefore, the reflex discharge and the anti-
dromic F-wave in these motor neurons would collide and prevent the H-reflex from being 
measured (in accord with observation) but also preventing the assessment of the F-wave. 
Therefore, the F-wave signal only takes into account the high-threshold motor neurons 
(where no H-reflex occurs) and so it is not useful to measure the change in excitability in 
low-threshold motor neurons. Moreover, backfiring of neurons is not completely 
understood and may well not be correlated with the intrinsic neuronal excitability (Lin and 
Floeter, 2004). Another assessment is usually needed to confirm the evolution of the F-
wave parameters and its correlation with excitability. The H-reflex is considered more 
accurate in this view as it accesses the same population of motor neurons as the majority 
of excitatory afferents and is correlated with the number of motor neurons recruited (Lin 
and Floeter, 2004). Regarding our study, we can confidently infer that we have an increase 
in excitability at day one following injection of VEGF as the increase in the F/M ratio is 
confirmed by an even greater increase in H/M ratio. 
 
VI.7.2- Role of astrocytes in hyperexcitability 
Several recent reports provide an explanation for why the leakage of blood components 
induced by VEGF could be responsible for the increase in excitability, and they have 
proposed different pathways that may be involved. 
 
First, it has been proposed that the release of vascular components by blood-brain barrier 
dysfunction can act on astroglial cells with consequences on neuronal excitability (Ivens et 
al., 2007; Seiffert et al., 2004). Astrocytes and endothelial cells are closely linked, being part 
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of the so-called neurovascular unit (Abbott et al., 2006). It is thus expected that alteration 
of the blood-brain barrier will affect astrocytic function. Indeed, leakage of albumin, which 
we showed by Evans blue leakage, can lead to its uptake by astrocytes (Ivens et al., 2007) 
and their activation (as assessed by GFAP over-expression) (Seiffert et al., 2004). Thrombin 
has also been shown to signal through PAR-1 receptors located on astrocytes (Junge et al., 
2004), which are receptors involved in astrocytic glutamate release (Lee and Haydon, 
2007). In our study, we showed that VEGF injection induces astroglial activation and GFAP 
over-expression, as described elsewhere (Krum et al., 2002). Astroglial activation can act on 
neuronal excitability through several mechanisms. Downregulation of the abundant 
astrocytic inward rectifying potassium channels (Kir4.1) and water channels (aquaporin 4) 
can have consequences on the extra-cellular ionic balance in the CNS, and this can affect 
neuronal excitability. For example, the failure of astrocytes to take up potassium results in 
an increase in external potassium which in turn leads to an increase of neuronal excitability 
by lowering the firing threshold, reducing the speed of repolarisation and facilitating 
activation of NMDA receptors (David et al., 2009).  
 
Astrocytes are also important for glutamate uptake and metabolism and evidence supports 
the hypothesis that impairment of astrocytic glutamate transporters can lead to 
development of epileptic seizures (Wetherington et al., 2008).  
 
VI.7.3- Role of inflammation 
A role of inflammation and more precisely of inflammatory cytokines released by astroglial 
and microglial cells, has also been investigated (Weissberg et al., 2011). IL-1β, 
cyclooxygenase-2, TNF-α, IL-6 and TGF-β have been shown to directly affect synaptic 
signalling and plasticity (Yu and Shinnick-Gallagher, 1994). For example, IL-1β reduces 
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glutamate uptake by astrocytes (Ye and Sontheimer, 1996) and enhances their TNF-α 
mediated glutamate release (Bezzi et al., 2001), and has been shown to exacerbate seizures 
in rodents (Vezzani et al., 1999) by enhancing NMDA mediated excitability (Vezzani and 
Baram, 2007). Inflammatory cells themselves have also been shown to release glutamate 
(Piani and Fontana, 1994). Albumin may also act on microglia to induce glutamate release 
(Hooper et al., 2009), thereby increasing neuronal excitability.  
 
VI.7.4- Direct role of plasma proteins in hyperexcitability 
Plasma proteins may also directly increase neuronal excitability. For example, IgG is present 
in the spinal cord of animals injected with VEGF at the time of hyperexcitability, and it can 
accumulate in neurons of epileptic patients (Rigau et al., 2007). Indeed, such accumulation 
has been linked to neuronal hyperexcitability (Michalak et al., 2012), and since IgG is 
present in the dorsal and ventral horns of animals injected with VEGF one day following 
surgery, it may be involved in the correlated increase in H/M and F/M ratios.  
 
Also, thrombin has been shown to potentiate NMDA receptor function and to increase 
neuronal excitability via binding to the PAR-1 receptor, thereby indicating a possible direct 
action on neurons (Gingrich et al., 2000). Moreover, thrombin can enhance the neuronal 
response to afferent stimulation (Maggio et al., 2008), and hence enhance the H reflex 
following sciatic nerve stimulation. We therefore hypothesize that the increase in H reflex 
amplitude following VEGF injection may be due to thrombin-induced excitability.  
 
The normal range of glutamate concentration in plasma is 50-100 µmol/L, but it is normally 
only 0.5-2 µmol/L in the extracellular fluid in the CNS (Hawkins, 2009). Leakage of plasma in 
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the CNS would therefore dramatically increase the extra-cellular glutamate concentration, 
thus contributing further to an increase in excitability. 
 
VI.7.5- Synaptic alterations in animals injected with VEGF 
Loss of the pre-synaptic marker synaptophysin occur in acute lesions in the grey matter of 
MS patients (Vercellino et al., 2005), associated with a high density of activated microglia 
(Vercellino et al., 2007). Furthermore, in EAE, a loss of these two synaptic markers occurred 
in the ventral horn and on dendrites located in the adjacent white matter, in correlation 
with inflammation and NMDA receptor activation (Zhu et al., 2003). These changes may be 
significant because in AD, loss of the synaptophysin is associated with reduction in 
glutamate uptake and excitotoxicity (Masliah et al., 1996), and degradation of PSD-95 
resulting from NMDA administration to organotypic hippocampal cultures is also associated 
with excitotoxicity (Lu et al., 2000). In light of the increase in excitability observed at day 
one following injection of VEGF, we characterized the synaptic state of neurons in the 
spinal cord by labelling sections for synaptophysin and PSD-95. Unexpectedly, no difference 
in either marker could be observed between animals injected with VEGF and controls at 
day one, when an increase in excitability is present, nor at day two, when a neurological 
deficit is present. This suggests that changes in neuronal conduction occurring at least at 
day one are not mediated by synaptic modification. As discussed earlier, an increase in 
extracellular glutamate without a decrease in synaptic function (i.e. the same amount of 
synaptophysin and PSD-95) would be expected to lead to an increase in excitability.  
 
The fact that the changes in electrophysiological properties observed at day one returned 
to baseline by day two, makes it less surprising that no change was detected at the synaptic 
level. However, this is in contrast to observations in MS patients and particularly in EAE, 
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where synaptic stripping and decreases in synaptic proteins have been reported (Trapp et 
al., 2007). The changes in MS have understandably been interpreted as an explanation for 
at least some of the loss of function, but the findings from our study suggest that such 
severe changes are not required. It seems that the structural changes in MS and EAE may 
require much stronger inflammation around neurons and dendrites than observed in our 
study, but that loss of function occurs even without these changes.  
 
VI.8- Relevance of this model to MS 
We believe that the lesion induced by VEGF is very relevant to understanding the 
pathophysiology of MS, especially with regard to the consequences of blood-brain barrier 
breakdown.  
 
VI.8.1- Blood-brain barrier breakdown 
Transient breakdown of the blood-brain barrier is a prominent feature of MS lesions (Leech 
et al., 2007), particularly during the relapsing/remitting phase of the disease where it is 
recognised as an early event during the formation of a new lesion (Cotton et al., 2003; 
Kermode et al., 1990) by MRI detection the leakage of gadolinium contrast medium 
(Kermode et al., 1990). Such blood-brain barrier breakdown is associated with the onset of 
neurological deficit, at least in optic neuritis, which often the first sign of MS (Youl et al., 
1991). This time course is comparable to ours since blood-brain barrier breakdown occurs 
before the onset of deficit. In other MS animal models, the leakage of plasma components 
into the CNS is also present. Again, it is often present before the onset of neurological 
deficit in EAE animals and disappears with the functional problems (Floris et al., 2004) as 
seen in our model.  
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VI.8.2- Functional deficit 
Second, the functional deficit we observed is consistently limited to the hind limbs and 
consists of an acute phase occurring two days following injection of VEGF followed by a 
remission the next day. This acute phase followed by remission is also observed in patients 
suffering from relapsing/remitting MS but also in animal models of MS, EAE (Hawkins et al., 
1991) and LPS (Felts et al., 2005; Marik et al., 2007). Our model can thus be a tool to 
explore the pathogenesis of this transient deficit.  
 
VI.8.3- VEGF 
The expression of VEGF has been shown to correlate with relapses in MS patients. Indeed, 
an increased concentration of VEGF is found in the serum of patients undergoing relapses, 
and this returns to normal during the remission phase (Su et al., 2006). In EAE, an increased 
expression of VEGF is also present and it is correlated with the inflammatory process 
observed in the tissue (Proescholdt et al., 2002a). These studies suggest that VEGF itself 
may play a role in the pathogenesis of MS, not only by opening the blood-brain barrier and 
exposing the brain to compounds it is normally shielded from, but also by inducing 
inflammation and attracting monocytes. Inducing a blood-brain barrier leakage in naive 
animals by injecting VEGF is therefore a useful tool to reproduce the blood-brain barrier 
alterations observed in MS. Moreover, the use of VEGF avoids the use of non-physiological 
agents that could lead to the triggering of non-physiological mechanisms and pathologies. 
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VI.8.4- Spasticity 
Spasticity is a very common symptom of MS, reported in 84% of patients (Rizzo et al., 
2004). Spasticity is thought to be due to a hyperexcitable state of the stretch reflex arc 
(Heckmann et al., 2005). The determination of the amplitudes of the H-reflex (Voerman et 
al., 2005) and F-wave (Argyriou et al., 2006; Lin and Floeter, 2004) provide quantitative 
methods available in the clinic to assess over excitability of neurons and thus spasticity, and 
these methods have already been used in MS patients to detect spasticity (Argyriou et al., 
2010; Bischoff et al., 1992; Smith et al., 1989; Voerman et al., 2005). Our results are in line 
with what has been found in MS patients, i.e. an increase in H-reflex and F-wave 
amplitudes occurs, while the M response remains constant (Argyriou et al., 2010). The 
VEGF lesion may prove to be an excellent model in later studies to investigate the pathways 
involved in spasticity. 
 
VI.8.5- Features of the preactive lesion 
As discussed in the introduction, MS lesions present some heterogeneity in their structure. 
Staging of MS lesions is a subject of controversy (van der Valk and De Groot, 2000) because 
of the difficulties to characterize a time frame of lesion evolution. One specific type or 
stage of lesion, called the (p)reactive lesion (De Groot et al., 2001), is thought to precede 
the demyelination that characterises active lesions (van der Valk and De Groot, 2000). In 
this type of lesion, there are clusters of activated microglia, but in the absence of T-cells 
and demyelination (van der Valk and Amor, 2009; van Horssen et al., 2012; van Noort et al., 
2011). This cellular pattern has similarities with what we observe in the VEGF lesion, 
suggesting that breakdown of the blood-brain barrier may trigger the formation of 
preactive lesions in MS. Whether the preactive lesions evolve into the classical ‘actively 
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demyelinating’ lesion is uncertain, although current belief is that many preactive lesions 
subside without any persistent pathology.  
The intraspinal injection of VEGF induces a transient (2-three days) breakdown of the 
blood-brain barrier breakdown, which is shorter than occurs in many MS lesions, based on 
gadolinium leakage (Cotton et al., 2003). It seems likely that such more chronic leakage 
would, of course, lead to a longer exposure of the CNS to plasma compounds and that this 
would exacerbate any damage. Particularly, it has been shown that blood components 
have toxic effects on oligodendrocytes and myelin protein expression (Juliet et al., 2009) 
and it seems likely that prolonged blood-brain barrier breakdown may contribute to, or 
even cause, the degeneration of oligodendrocytes in actively demyelinating lesions.  
 
 
VI.9- Concluding remark 
It is sometimes said that all animal models are wrong, but that some are useful.  We agree, 
and believe that the VEGF lesion may not only prove to be more useful than many models, 
but also that it may illuminate the mechanisms operating in MS to cause the potentially 
devastating symptoms.  If so, the lesion may provide an avenue to elucidate the underlying 
mechanisms, and thereby provide the information needed to devise novel and effective 
therapeutic strategies.   
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